image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
f15d7bdbfa3ca446a0fa6cfc6699259fd4d097502d0fee2780769dd1aa2789d2.png | simple | <table><tr><td></td><td></td><td>B2</td><td>HTK</td><td>Euro Collins </td></tr><tr><td>Osmolality (mosm/kg)</td><td></td><td>323</td><td>310</td><td>406</td></tr><tr><td>Ions (mmol/l)</td><td>Na<sup>+</sup></td><td>22</td><td>15</td><td>10</td></tr><tr><td></td><td>K<sup>+</sup></td><td>150</td><td>9</td><td>115</td></... | <table><tr><td></td><td></td><td>B2</td><td>HTK</td><td>Euro Collins</td></tr><tr><td>Osmolality (mosm/kg)</td><td></td><td>323</td><td>310</td><td>406</td></tr><tr><td>Ions (mmol/l)</td><td>Na+</td><td>22</td><td>15</td><td>10</td></tr><tr><td></td><td>K+</td><td>150</td><td>9</td><td>115</td></tr><tr><td></td><td>Mg+... | <table><tr><td>Osmotics (mmol/l)</td><td>Glucose</td><td></td><td></td><td>198</td></tr><tr><td></td><td>Mannitol</td><td></td><td>30</td><td></td></tr><tr><td></td><td>Saccharin</td><td>40</td><td></td><td></td></tr><tr><td>Colloids (mmol/l)</td><td>PEG</td><td>25</td><td></td><td></td></tr></table> |
71d91f59326e819e716b4352ecd8e0ea544d58dda15907399fab350f9f90132e.png | simple | <table><tr><td>Primer name</td><td>Oligonucleotide</td><td>Product length</td><td>Product name</td></tr><tr><td><i>crdPG-1</i></td><td>GTACTCGAGATTGTCGGCAGTCCAG</td><td>607</td><td><i>crdP</i></td></tr><tr><td><i>crdPG-2</i></td><td>AGCTCCTCGCCCTTGCTCACCATGAAATCAACTCCTCTGT</td><td></td><td></td></tr><tr><td>GFP-1</td><... | <table><tr><td>Primer name</td><td>Oligonucleotide</td><td>Product length</td><td>Product name</td></tr><tr><td>crdPG-1</td><td>GTACTCGAGATTGTCGGCAGTCCAG</td><td>607</td><td>crdP</td></tr><tr><td>crdPG-2</td><td>AGCTCCTCGCCCTTGCTCACCATGAAATCAACTCCTCTGT</td><td></td><td></td></tr><tr><td>GFP-1</td><td>ACAGAGGAGTTGATTTCA... | <table><tr><td>Primer name</td><td>Oligonucleotide</td><td>Product length</td><td>Product name</td></tr><tr><td>crdP-2</td><td>CATGAAATCAACTCCTCTGT</td><td>607</td><td>crdP</td></tr><tr><td>crdP142-1</td><td>ATCGTCAGATGCCTATTTGT</td><td>537</td><td>crdP</td></tr><tr><td>crdP108-1</td><td>AAATTAGTTAATGCAAT</td><td>503</... |
02fa9e3b3695bb07995a91c076ffd9114130a8bef740627554a03214d9a49819.png | simple | <table><tr><td>lectin</td><td>time (dpi/dpe)<sup>a</sup></td><td>mucus<sup>b</sup></td><td>SMC<sup>c</sup></td><td>MNC<sup>d</sup></td></tr><tr><td>UEAI</td><td>0</td><td>+/-</td><td>-</td><td>++</td></tr><tr><td></td><td>14</td><td>+/-</td><td>+/-</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>++<... | <table><tr><td>lectin</td><td>time (dpi/dpe)a</td><td>mucusb</td><td>SMCc</td><td>MNCd</td></tr><tr><td>UEAI</td><td>0</td><td>+/-</td><td>-</td><td>++</td></tr><tr><td></td><td>14</td><td>+/-</td><td>+/-</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>++</td></tr><tr><td></td><td>60</td><td>+</td><... | <table><tr><td>WGA</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>14</td><td>++</td><td>++</td><td>++</td></tr><tr><td></td><td>21</td><td>+</td><td>+</td><td>+</td></tr><tr><td></td><td>60</td><td>+</td><td>+</td><td>+</td></tr><tr><td>RCA120</td><td>0</td><td>++</td><td>++</td><td>++</td></tr><t... |
405ee029d57ac9a6a14682fb572ab9fbf106ca3f216a07d6bd2bb2349c5c39f1.png | complex | <table><tr><td rowspan="2">HRV Index</td><td rowspan="2">Sitting Variable</td><td colspan="4">Crude Model (<i>N</i> = 126)</td><td colspan="4">Primary Adjusted Model (<i>N</i> = 126)</td></tr><tr><td>B</td><td>95%CI Low</td><td>High</td><td><i>p</i></td><td>B</td><td>95%CI Low</td><td>High</td><td><i>p</i></td></tr><tr... | <table><tr><td rowspan="2">HRV Index</td><td rowspan="2">Sitting Variable</td><td colspan="4">Crude Model (N = 126)</td><td>Primary Adjusted Model (N = 126)</td></tr><tr><td>B</td><td>95%CI Low</td><td>High</td><td>p</td><td>B</td></tr><tr><td>IBI (ms)</td><td>Occupational sitting</td><td>−17.00</td><td>−35.80</td><td>... | <table><tr><td colspan="3">Primary Adjusted Model (N = 126)</td></tr><tr><td>95%CI Low</td><td>High</td><td>p</td></tr><tr><td>−46.98</td><td>−1.50</td><td>0.04</td></tr><tr><td>−14.43</td><td>−15.25</td><td>0.96</td></tr><tr><td>−8.88</td><td>−1.05</td><td>0.01</td></tr><tr><td>−0.73</td><td>4.38</td><td>0.16</td></tr... |
f631aa3f4a2f8daf322cde303f21a16276a8cd29ecd8e1517ca0b835913511a4.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">24‐hr mean <i>T</i><sub>b</sub> (°C)</td><td colspan="2">24‐hr maximum <i>T</i><sub>b</sub> (°C)</td></tr><tr><td>No feed</td><td>Feed</td><td>No feed</td><td>Feed</td></tr><tr><td colspan="5"><i>Sex</i></td></tr><tr><td>Male (<i>n</i> = 10)</td><td>... | <table><tr><td rowspan="2"></td><td colspan="2">24‐hr mean Tb (°C)</td><td colspan="2">24‐hr maximum Tb (°C)</td></tr><tr><td>No f</td><td>Fee</td><td>No fe</td><td>Feed</td></tr></table> | <table><tr><td></td><td>eed</td><td>d</td><td>ed</td><td></td></tr><tr><td colspan="5">Sex</td></tr><tr><td>Male (n = 10)</td><td>37.4 ± 0.1</td><td>37.8 ± 0.2</td><td>38.3 ± 0.2</td><td>38.8 ± 0.2</td></tr><tr><td>Female (n = 3)</td><td>37.6 ± 0.2</td><td>37.9 ± 0.2</td><td>38.5 ± 0.4</td><td>39.1 ± 0.3</td></tr></tab... |
50a94dab4a1ce3e9c4e4b57a2e32f154c819b6005ae34e90eab5c91d6211678d.png | complex | <table><tr><td></td><td></td><td colspan="2">Intervention (home visit)</td><td></td></tr><tr><td>Variable</td><td></td><td>No (<i>N</i> = 221)</td><td>Yes (<i>N</i> = 262)</td><td><i>P</i>-value</td></tr><tr><td colspan="5">Age (years)</td></tr><tr><td></td><td>Age (±SD)</td><td>30.40 ± 8.57</td><td>30.49 ... | <table><tr><td></td><td></td><td colspan="2">Intervention (home visit)</td><td></td></tr><tr><td>Variable</td><td></td><td>No (N = 221)</td><td>Yes (N = 262)</td><td>P-value</td></tr><tr><td colspan="5">Age (years)</td></tr><tr><td></td><td>Age (±SD)</td><td>30.40 ± 8.57</td><td>30.49 ± 7.84</td><td>0.90</td></tr><tr><... | <table><tr><td></td><td>Employed</td><td>141 (63.8 %)</td><td>164 (62.60 %)</td><td>0.78</td></tr><tr><td colspan="5">Number of children (N, %)</td></tr><tr><td></td><td>0–2</td><td>95 (42.99 %)</td><td>126 (57.01 %)</td><td rowspan="2">0.54</td></tr><tr><td></td><td>3 > 5</td><td>120 (45.80 %)</td><td>142 (54.20 %)</t... |
0c83a1147e3740adb25b22a353b46b90d5501549ebe45119e05a4d5f5eeb6940.png | simple | <table><tr><td>Preparation</td><td>Average finish line width (mm)</td></tr><tr><td>CCC 46</td><td>0.5</td></tr><tr><td>MCC 24</td><td>(0.5 + 1.2)/2 = 0.85</td></tr><tr><td>MCC 46</td><td>(0.5 + 0.8)/2 = 0.65</td></tr><tr><td>ACC 21</td><td>1</td></tr></table> | <table><tr><td>Preparation</td></tr><tr><td>CCC 46</td></tr><tr><td>MCC 24</td></tr><tr><td>MCC 46</td></tr><tr><td>ACC 21</td></tr></table> | <table><tr><td>Average finish line width (mm)</td></tr><tr><td>0.5</td></tr><tr><td>(0.5 + 1.2)/2 = 0.85</td></tr><tr><td>(0.5 + 0.8)/2 = 0.65</td></tr><tr><td>1</td></tr></table> |
685a7b6d4c8cab5d594648324ae46b7d3c3a714af7c620f7010a241bceb3ce16.png | complex | <table><tr><td rowspan="2">Peptide</td><td colspan="3">COX-1</td><td colspan="3">COX-2</td></tr><tr><td>be</td><td>ir</td><td>hb</td><td>be</td><td>ir</td><td>hb</td></tr><tr><td>GMD</td><td>−1.20</td><td>23</td><td>1</td><td>−39.87</td><td>21</td><td>3</td></tr><tr><td>GHE</td><td>−0.56</td><td>25</t... | <table><tr><td rowspan="2">Peptide</td><td colspan="2">COX-1</td></tr><tr><td>be</td><td>ir</td></tr><tr><td>GMD</td><td>−1.20</td><td>23</td></tr><tr><td>GHE</td><td>−0.56</td><td>25</td></tr><tr><td>YYV</td><td>—</td><td>—</td></tr></table> | <table><tr><td>COX-1</td><td colspan="3">COX-2</td></tr><tr><td>hb</td><td>be</td><td>ir</td><td>hb</td></tr><tr><td>1</td><td>−39.87</td><td>21</td><td>3</td></tr><tr><td>0</td><td>−42.15</td><td>26</td><td>5</td></tr><tr><td>—</td><td>—</td><td>—</td><td>—</td></tr></table> |
e2397db4488c776e18dd9b47f396e2202806fccd8849626da8a98eb717712f27.png | complex | <table><tr><td>Antibody</td><td colspan="4">Growth inhibition (%) over the period of cultivation</td></tr><tr><td>1 mg/ml IgG</td><td colspan="4"></td></tr><tr><td></td><td>Day 1</td><td>Day 2</td><td>Day 3</td><td>Day 4</td></tr><tr><td>GST</td><td>9.5±9.9</td><td>5.3±5.5</td><td>10.7±7.4</td><td>10.5&#... | <table><tr><td>Antibody</td><td colspan="4">Growth inhibition (%) over the period of cultivation</td></tr><tr><td>1 mg/ml IgG</td><td colspan="4"></td></tr><tr><td></td><td>Day 1</td><td>Day 2</td><td>Day 3</td><td>Day 4</td></tr></table> | <table><tr><td>GST</td><td>9.5±9.9</td><td>5.3±5.5</td><td>10.7±7.4</td><td>10.5±3.7</td></tr><tr><td>BbTRAP2</td><td>55.3±6.1*</td><td>48.1±5.6*</td><td>59.1±4.4*, **</td><td>73.6±4*, **</td></tr><tr><td>BbRAP-1CT</td><td>54.2±9.1*</td><td>45.9±8.2*</td><td>45.3±4.7*</td><td>60.9±5.4*</td></tr><tr><td>BbMSA-2c</td><td... |
7a0b5fc576fcc9ae4b83f9df105978c8d3efdc33dede17bd460f67298966d80d.png | simple | <table><tr><td>TB CX-test</td><td>AFB staining (+)</td><td>AFB staining (−)</td><td>Totals</td></tr><tr><td>TB CX-test(+)</td><td>12</td><td>1*</td><td>13</td></tr><tr><td>TB CX-test(−)</td><td>0</td><td>83</td><td>83</td></tr><tr><td>Totals</td><td>12</td><td>84</td><td>96</td></tr></table> | <table><tr><td>TB CX-test</td><td>AFB staining (+)</td><td>AFB staining (−)</td><td>Totals</td></tr><tr><td>TB CX-test(+)</td><td>12</td><td>1*</td><td>13</td></tr><tr><td>TB CX-test(−)</td><td>0</td><td>83</td><td>83</td></tr></table> | <table><tr><td>Totals</td><td>12</td><td>84</td><td>96</td></tr></table> |
e370057b32d6f60868bff32a5daec331bcc6d4c058c4d953f70287c461f096d1.png | simple | <table><tr><td><i>Variable</i></td><td><i>Max</i></td><td><i>Min</i></td><td><i>Mean</i></td><td><i>SD</i></td></tr><tr><td>“Income”</td><td>550.00</td><td>0.00</td><td>42.33</td><td>42.65</td></tr><tr><td>“Spent”</td><td>425.00</td><td>1.97</td><td>25.42</td><td>36.86</td></tr><tr><td>“Pi... | <table><tr><td>Variable</td><td>Max</td><td>Min</td><td>Mean</td><td>SD</td></tr><tr><td>“Income”</td><td>550.00</td><td>0.00</td><td>42.33</td><td>42.65</td></tr><tr><td>“Spent”</td><td>425.00</td><td>1.97</td><td>25.42</td><td>36.86</td></tr></table> | <table><tr><td>“Pins”</td><td>0.90</td><td>0.00</td><td>0.58</td><td>0.23</td></tr></table> |
650ddc8f908c2530ed6ffa1d7f2d5e9905654600a7f16d9ef827c1e527bc1bb3.png | simple | <table><tr><td>Variables</td><td>Mean</td><td>95% CI of the mean</td><td>Statistics (<i>P</i> values)</td></tr><tr><td>IBS symptom score</td><td>1.57</td><td>0.10; 3.05</td><td><i>P</i> = 0.04</td></tr><tr><td>Bacteroides</td><td>−0.01</td><td>−0.11; 0.08</td><td>ns (<i>P</i> = 0.77)</td></tr><tr><td>Faecal... | <table><tr><td>Variables</td><td>Mean</td><td>95% CI of the mean</td><td>Statistics (P values)</td></tr><tr><td>IBS symptom score</td><td>1.57</td><td>0.10; 3.05</td><td>P = 0.04</td></tr><tr><td>Bacteroides</td><td>−0.01</td><td>−0.11; 0.08</td><td>ns (P = 0.77)</td></tr><tr><td>Faecalibacterium</td><td>−0.03</td><td>... | <table><tr><td>Lachnospiraceae</td><td>0.05</td><td>−0.03; 0.13</td><td>ns (P = 0.18)</td></tr><tr><td>“Common” Simpson's D</td><td>−0.04</td><td>−0.15; 0.08</td><td>ns (P = 0.50)</td></tr></table> |
9744cc1ccdf3131f2a22be41f3eb022036e9ee8e4459906d8fa10ccf0fdb7b50.png | complex | <table><tr><td rowspan="2"> </td><td rowspan="2">I</td><td colspan="4"><i>T</i><sub>a </sub>(°C)</td></tr><tr><td>400</td><td>450</td><td>500</td><td>550</td></tr><tr><td rowspan="4">Average height (AH) [nm]</td><td>(111)A</td><td>23.4</td><td>25.4</td><td>28.9</td><td>32.2</td></tr><tr><td>(110)</td><td>22.6</td>... | <table><tr><td rowspan="2"></td><td rowspan="2">I</td><td colspan="4">Ta (°C)</td></tr><tr><td>400</td><td>450</td><td>500</td><td>550</td></tr><tr><td rowspan="4">Average height (AH) [nm]</td><td>(111)A</td><td>23.4</td><td>25.4</td><td>28.9</td><td>32.2</td></tr><tr><td>(110)</td><td>22.6</td><td>24.7</td><td>28.2</t... | <table><tr><td rowspan="3">l diameter (LD) [nm]</td><td>110)</td><td>2.5</td><td></td><td>133.8</td><td></td></tr><tr><td>(100)</td><td>115</td><td>124.5</td><td>130.8</td><td>139.1</td></tr><tr><td>(111)B</td><td>106.2</td><td>115.5</td><td>123.5</td><td>133.1</td></tr><tr><td rowspan="4">Average density (AD) [×108 cm... |
0b4dd4d3b07343a19c30729e888aaf106bfe31b96a570c698e8f8a66fb30f033.png | complex | <table><tr><td>Reason</td><td>No. of patients</td><td>% patients</td></tr><tr><td colspan="3">Presence of any types of primary disease progression (n = 26)</td></tr><tr><td>Enlargement of tumor</td><td>14</td><td>47</td></tr><tr><td>Elevation of tumor marker</td><td>7</td><td>23</td></tr><tr><td>Carcinomatous pain</td>... | <table><tr><td>Reason</td><td>No. of patients</td></tr><tr><td colspan="2">Presence of any types of primary disease progression (n = 26)</td></tr><tr><td>Enlargement of tumor</td><td>14</td></tr><tr><td>Elevation of tumor marker</td><td>7</td></tr><tr><td>Carcinomatous pain</td><td>5</td></tr><tr><td>Obstructive jaundi... | <table><tr><td>% patients</td></tr><tr><td>Presence of any types of primary disease progression (n = 26)</td></tr><tr><td>47</td></tr><tr><td>23</td></tr><tr><td>17</td></tr><tr><td>17</td></tr><tr><td>7</td></tr><tr><td>Absence of disease progression (n = 4)</td></tr><tr><td>13</td></tr></table> |
ec07a5032d8702ce95565fabfba065ee781e5613a275cc64c5ecd2c02e310db6.png | simple | <table><tr><td>Antibodies</td><td>Manufacturer</td><td>Source</td><td>Reactivity</td><td>Dilution</td></tr><tr><td>CD34</td><td>Sigma</td><td>Mouse</td><td>Rat</td><td>1:100</td></tr><tr><td>5-HT</td><td>Immunostar</td><td>Rabbit</td><td>Rat</td><td>1:20,000</td></tr><tr><td>GFAP</td><td>Millipore</td><td>Rabbit</td><t... | <table><tr><td>Antibodies</td></tr><tr><td>CD34</td></tr><tr><td>5-HT</td></tr><tr><td>GFAP</td></tr><tr><td>APC</td></tr><tr><td>NeuN</td></tr></table> | <table><tr><td>Manufacturer</td><td>Source</td><td>Reactivity</td><td>Dilution</td></tr><tr><td>Sigma</td><td>Mouse</td><td>Rat</td><td>1:100</td></tr><tr><td>Immunostar</td><td>Rabbit</td><td>Rat</td><td>1:20,000</td></tr><tr><td>Millipore</td><td>Rabbit</td><td>Rat</td><td>1:50</td></tr><tr><td>Calbiochem</td><td>Mou... |
1771cf213ddf45a3c88966e68cfb19ccd1efde7f0e2dc4c99e2281ac158e2994.png | simple | <table><tr><td>sTNF/TNFR1 signaling</td><td> </td></tr><tr><td>sTNF is necessary for the induction of autoimmune diseases [160]</td><td> </td></tr><tr><td>Association of TNF and TNFR1 polymorphisms with PD risk [14, 163]</td><td> </td></tr><tr><td>Association of TNFR1 polymorphism with MS risk [164]</td><td> </td></tr>... | <table><tr><td>sTNF/TNFR1 signaling</td><td></td></tr><tr><td>sTNF is necessary for the induction of autoimmune diseases [160]</td><td></td></tr><tr><td>Association of TNF and TNFR1 polymorphisms with PD risk [14, 163]</td><td></td></tr><tr><td>Association of TNFR1 polymorphism with MS risk [164]</td><td></td></tr><tr>... | <table><tr><td>TNFR2 promotes OPC proliferation and remyelination [176]</td></tr><tr><td>TNFR2 protects neurons against glutamate-induced excitotoxicity [142, 143]</td></tr><tr><td>memTNF dependent activation of NFkB is neuroprotective in EAE [171]</td></tr><tr><td>TNFR2 rescues neurons from oxidative stress-induced ce... |
e70b22037fc754144623387958601c26a41bb363bc4a81d7ab7d6bce02ab03a0.png | simple | <table><tr><td>Structure</td><td>Damage Scale</td><td>Stiffness Adjustment</td><td>Flatfoot Stiffness (N/mm)</td></tr><tr><td>Superomedial spring</td><td>Stage IV</td><td>−7/8th</td><td>39</td></tr><tr><td>Inferomedial spring</td><td>Stage II</td><td>−3/8th</td><td>94</td></tr><tr><td>Talocalcaneal inteross... | <table><tr><td>Structure</td><td>Damage Scale</td><td>Stiffness Adjustment</td><td>Flatfoot Stiffness (N/mm)</td></tr><tr><td>Superomedial spring</td><td>Stage IV</td><td>−7/8th</td><td>39</td></tr><tr><td>Inferomedial spring</td><td>Stage II</td><td>−3/8th</td><td>94</td></tr><tr><td>Talocalcaneal interosseus</td><td>... | <table><tr><td>Plantar metatarsocuneiform</td><td>Stage 0</td><td>None</td><td>90</td></tr><tr><td>Plantar naviculocuneiform</td><td>Stage 0</td><td>None</td><td>180</td></tr><tr><td>Long and short plantar</td><td>Stage 0</td><td>None</td><td>240</td></tr><tr><td>Deep deltoid</td><td>Stage 0</td><td>None</td><td>200</t... |
351638ac85eb5236645cefab448cc52cca40e9cd703b5a968b1ea42396b21cfe.png | simple | <table><tr><td>Usage</td><td>AAindex ID</td><td>Physicochemical properties</td></tr><tr><td>100%</td><td>MEEJ800102</td><td>Retention coefficient in HPLC, pH2.1</td></tr><tr><td>91%</td><td>WOLS870102</td><td>Principal property value z2</td></tr><tr><td>87%</td><td>CASG920101</td><td>Hydrophobicity scale from native pr... | <table><tr><td>Usage</td><td>AAindex ID</td><td>Physicochemical properties</td></tr><tr><td>100%</td><td>MEEJ800102</td><td>Retention coefficient in HPLC, pH2.1</td></tr><tr><td>91%</td><td>WOLS870102</td><td>Principal property value z2</td></tr><tr><td>87%</td><td>CASG920101</td><td>Hydrophobicity scale from native pr... | <table><tr><td>Usage</td><td>AAindex ID</td><td>Physicochemical properties</td></tr><tr><td>56%</td><td>TANS770109</td><td>Normalized frequency of coil</td></tr></table> |
330c5c8fbd6d56041b50591f075f53162948f87c5711fcbd8a80c06d3a490945.png | complex | <table><tr><td></td><td>All patients (<i>n</i> = 1119)</td><td>LBBB (<i>n</i> = 221)</td><td>RBBB (<i>n</i> = 82)</td><td>IVCD (<i>n</i> = 67)</td><td>Narrow QRS (<i>n</i> = 749)</td><td><i>P</i> value</td></tr><tr><td>Age (years)</td><td>51.1 ± 14.7</td><td>57.2 ± 12.0</td><td>53.1 ± 14.7</td><td>52.3 &... | <table><tr><td></td><td>All patients (n = 1119)</td><td>LBBB (n = 221)</td><td>RBBB (n = 82)</td><td>IVCD (n = 67)</td><td>Narrow QRS (n = 749)</td><td>P value</td></tr><tr><td>Age (years)</td><td>51.1 ± 14.7</td><td>57.2 ± 12.0</td><td>53.1 ± 14.7</td><td>52.3 ± 14.5</td><td>48.9 ± 14.9</td><td><0.001a</td></tr><tr><t... | <table><tr><td>Disease duration (years)</td><td>2(0.5–6)</td><td>4(1–9)</td><td>4(1–8)</td><td>3(1.5–6)</td><td>2(0.35–5)</td><td>0.001</td></tr><tr><td>Essential hypertension, n (%)</td><td>294(26.3)</td><td>73(33.0)</td><td>15(18.3)</td><td>15(22.4)</td><td>191(25.5)</td><td>0.034</td></tr><tr><td>Diabetes mellitus, ... |
8e413acbb521002dcc117eb0865f50563dccd173d9d111af80b6e2563c89a230.png | complex | <table><tr><td rowspan="2">Treatment groups</td><td colspan="2">Continuous exposure profile</td><td colspan="2">Cross-over exposure profile</td></tr><tr><td>CC</td><td>TT</td><td>CT</td><td>TC</td></tr><tr><td>CC</td><td></td><td>42</td><td>53</td><td>42</td></tr><tr><td>TT</td><td>42</td><td></td><td>36</td><td>31</td... | <table><tr><td rowspan="2">Treatment groups</td><td colspan="2">Continuous exposure profile</td></tr><tr><td>CC</td><td>TT</td></tr><tr><td>CC</td><td></td><td>42</td></tr><tr><td>TT</td><td>42</td><td></td></tr><tr><td>CT</td><td>53</td><td>36</td></tr><tr><td>TC</td><td>42</td><td>31</td></tr></table> | <table><tr><td colspan="2">Cross-over exposure profile</td></tr><tr><td>CT</td><td>TC</td></tr><tr><td>53</td><td>42</td></tr><tr><td>36</td><td>31</td></tr><tr><td></td><td>39</td></tr><tr><td>39</td><td></td></tr></table> |
477427e14544cf8b4d86bcb90d99578468231858031f13e6dec36f9f5185b5a9.png | simple | <table><tr><td><i>XXY ID</i></td><td><i>Sequence (XX_Y)</i></td><td><i>N Species</i></td><td><i>freq (%)</i></td><td><i>N changes*</i></td></tr><tr><td>1</td><td>AAaTGAAGAAAAcGAAGA_ATGAAGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>2</td><td>AAaTGAAGAAAATGAAGA_ATGAAGA</td><td>27</td><td>28.42</td><td>1</td></tr>... | <table><tr><td>XXY ID</td><td>Sequence (XX_Y)</td><td>N Species</td><td>freq (%)</td><td>N changes*</td></tr><tr><td>1</td><td>AAaTGAAGAAAAcGAAGA_ATGAAGA</td><td>2</td><td>2.11</td><td>2</td></tr><tr><td>2</td><td>AAaTGAAGAAAATGAAGA_ATGAAGA</td><td>27</td><td>28.42</td><td>1</td></tr><tr><td>3</td><td>AAaTGAAGAAAATGAAG... | <table><tr><td>XXY ID</td><td>Sequence (XX_Y)</td><td>N Species</td><td>freq (%)</td><td>N changes*</td></tr><tr><td>10</td><td>AACTGAAGAAAATGAAGA_ATGAAGA</td><td>40</td><td>42.11</td><td>0</td></tr><tr><td>11</td><td>AACTGAAGAcAATGAAGA_ATGAAGA</td><td>3</td><td>3.16</td><td>1</td></tr><tr><td>12</td><td>cAgTGAAGAAAATG... |
3a1a9be4682b1b0020d79ee4438a467ef50ca77cc37d619a3970c6b1036186a5.png | simple | <table><tr><td>Participants</td><td>Nationality</td><td>Sex</td><td>Age category</td><td>Migratory status</td><td>Health complaints</td><td>Received treatments while undocumented migrant in Denmark</td></tr><tr><td>P01</td><td>Bangladeshi</td><td>Male</td><td>31-40</td><td>Failed asylum seeker</td><td>Dental problems, ... | <table><tr><td>Participants</td><td>Nationality</td><td>Sex</td><td>Age category</td><td>Migratory status</td><td>Health complaints</td><td>Received treatments while undocumented migrant in Denmark</td></tr><tr><td>P01</td><td>Bangladeshi</td><td>Male</td><td>31-40</td><td>Failed asylum seeker</td><td>Dental problems, ... | <table><tr><td>Participants</td><td>Nationality</td><td>Sex</td><td>Age category</td><td>Migratory status</td><td>Health complaints</td><td>Received treatments while undocumented migrant in Denmark</td></tr><tr><td>P07</td><td>Nepali</td><td>Male</td><td>21-30</td><td>Overstayer</td><td>None</td><td>None</td></tr><tr><... |
587806a7e81461905248c0ba60223492a95de4058bf68fd9ed3ca2d21c6cd781.png | simple | <table><tr><td></td><td>Linear model</td><td>Ordered probit model</td></tr><tr><td>Men 15-44</td><td></td><td></td></tr><tr><td>Gap in VAS</td><td>0.196</td><td>0.186</td></tr><tr><td>Prevalence effect</td><td>-0.082</td><td>-0.102</td></tr><tr><td>Severity effect</td><td>0.239</td><td>0.030</td></tr><tr><td>Interactio... | <table><tr><td></td><td>Linear model</td><td>Ordered probit model</td></tr><tr><td>Men 15-44</td><td></td><td></td></tr><tr><td>Gap in VAS</td><td>0.196</td><td>0.186</td></tr><tr><td>Prevalence effect</td><td>-0.082</td><td>-0.102</td></tr><tr><td>Severity effect</td><td>0.239</td><td>0.030</td></tr><tr><td>Interactio... | <table><tr><td>men 65-74</td><td></td><td></td></tr><tr><td>Difference</td><td>-0.902</td><td>-0.664</td></tr><tr><td>Prevalence effect</td><td>-0.575</td><td>-0.699</td></tr><tr><td>Severity effect</td><td>0.305</td><td>0.372</td></tr><tr><td>Interaction</td><td>-0.632</td><td>-0.646</td></tr><tr><td>Women 75 & more</... |
0d4bb2438e392ba0f24139e02426d9aae73137f00248a4389b944f1f4eea919b.png | complex | <table><tr><td>Study</td><td>Criteria used for prophylaxis</td><td>Antifungal used for prophylaxis</td><td>Invasive candidiasis</td><td>Commentary</td></tr><tr><td colspan="5">Positive prophylactic studies</td></tr><tr><td>*Slotman et al.1987 [77]</td><td>Abdominal surgery+ ≥ 3 risk factors</td><td>Ketoconazole 2... | <table><tr><td>Study</td><td>Criteria used for prophylaxis</td><td>Antifungal used for prophylaxis</td><td>Invasive candidiasis</td><td>Commentary</td></tr><tr><td colspan="5">Positive prophylactic studies</td></tr><tr><td>*Slotman et al.1987 [77]</td><td>Abdominal surgery+ ≥ 3 risk factors</td><td>Ketoconazole 200 mg/... | <table><tr><td>Schuster et al.2008 [83]*</td><td>ICU ≥ 4 d+ Fever > 4 d under broad-spectrum antibiotics+ APACHE II ≥ 16</td><td>Fluconazole 400 mg/d IVPlacebo</td><td>6/122 (5%)11/127 (9%)‡</td></tr></table> |
28e2083b97471052974b613071ac37e9d745a7cdc5c6ad86f1e30c4fb4c8382b.png | simple | <table><tr><td>Ptosis</td><td>Group A</td><td>Group B</td></tr><tr><td>Excellent</td><td>89% (57)</td><td>83.9% (52)</td></tr><tr><td>Good</td><td>9.4% (6)</td><td>9.7% (6)</td></tr><tr><td>Fair</td><td>1.6% (1)</td><td>6.4% (4)</td></tr><tr><td>Poor</td><td></td><td></td></tr><tr><td>Very poor</td><td></td><td></td></... | <table><tr><td>Ptosis</td><td>Group A</td><td>Group B</td></tr><tr><td>Excellent</td><td>89% (57)</td><td>83.9% (52)</td></tr><tr><td>Good</td><td>9.4% (6)</td><td>9.7% (6)</td></tr><tr><td>Fair</td><td>1.6% (1)</td><td>6.4% (4)</td></tr><tr><td>P</td><td></td><td></td></tr></table> | <table><tr><td>Ptosis</td><td>Group A</td><td>Group B</td></tr><tr><td>oor</td><td></td><td></td></tr><tr><td>Very poor</td><td></td><td></td></tr><tr><td>p value</td><td>0.440</td><td></td></tr></table> |
e2612df633e02c397767c390e5611497d0ad65bc717ec873cfda0df22a949ffd.png | complex | <table><tr><td>NHANES 2001–2010<sup><i>a</i></sup></td><td>Sample size</td><td>Unweighted percent, %</td></tr><tr><td>All</td><td>9,568</td><td>100.0</td></tr><tr><td>Sex</td></tr><tr><td>Male</td><td>4,690</td><td>49.0</td></tr><tr><td>Female</td><td>4,878</td><td>51.0</td></tr><tr><td>Age (years)</td></tr><tr><... | <table><tr><td>NHANES 2001–2010a</td><td>Sample size</td><td>Unweighted percent, %</td></tr><tr><td>All</td><td>9,568</td><td>100.0</td></tr><tr><td>Sex</td><td colspan="2"></td></tr><tr><td>Male</td><td>4,690</td><td>49.0</td></tr><tr><td>Female</td><td>4,878</td><td>51.0</td></tr><tr><td>Age (years)</td><td colspan="... | <table><tr><td>NHANES 2001–2010a</td><td>Sample size</td><td>Unweighted percent, %</td></tr><tr><td>Non-Hispanic white</td><td>4,280</td><td>44.7</td></tr><tr><td>Non-Hispanic black</td><td>1,802</td><td>18.8</td></tr><tr><td>Mexican American</td><td>2,264</td><td>23.7</td></tr><tr><td>Other</td><td>1,222</td><td>12.8<... |
eaccd4fc0288068d0343323d33e1bcb631f923b1bd70c2ed401ef77da7d90e32.png | simple | <table><tr><td>Gene</td><td>Forward (5′-3′)</td><td>Reverse (5′-3′)</td></tr><tr><td>Egr1</td><td>AACAACCCTACGAGCACCTG</td><td>AAAGGGGTTCAGGCCACAAA</td></tr><tr><td>Fgf2</td><td>GCGACCCACACGTCAAACTA</td><td>CCGTGACCGGTAAGTGTTGTA</td></tr><tr><td>Fgf7</td><td>TGTGGCAATCAAAGGGGTGG</td><td>AAGGCCAC... | <table><tr><td>Gene</td><td>Forward (5′-3′)</td><td>Reverse (5′-3′)</td></tr><tr><td>Eg</td><td>AACAACCCTACGAGCAC</td><td>AAAGGGGTTCAGGCCAC</td></tr></table> | <table><tr><td>r1</td><td>CTG</td><td>AAA</td></tr><tr><td>Fgf2</td><td>GCGACCCACACGTCAAACTA</td><td>CCGTGACCGGTAAGTGTTGTA</td></tr><tr><td>Fgf7</td><td>TGTGGCAATCAAAGGGGTGG</td><td>AAGGCCACGAACATTTCCCC</td></tr><tr><td>Jak2</td><td>AGTGTGCTACAGTGCTGGTC</td><td>TTCCTTGTTGCCAGATCCCG</td></tr><tr><td>Mmp9</td><td>GCCGGGA... |
352c4bce167263351912432fa7c3e737097a94db30cf2769098f67891b53e10d.png | complex | <table><tr><td>Category</td><td>Data Elements</td></tr><tr><td rowspan="5">Vascular Access</td><td>Dialysis catheter position</td></tr><tr><td>Dialysis catheter type (acute or tunneled)</td></tr><tr><td>Dialysis catheter manufacturer</td></tr><tr><td>Dialysis catheter size</td></tr><tr><td>Any need for catheter manipul... | <table><tr><td>Category</td></tr><tr><td rowspan="5">Vascular Access</td></tr><tr></tr><tr></tr><tr></tr><tr></tr><tr><td rowspan="2">CRRT Circuit</td></tr><tr></tr><tr><td rowspan="3">CRRT-Related Anticoagulation</td></tr><tr></tr><tr></tr><tr><td rowspan="3">CRRT Fluids</td></tr><tr></tr><tr></tr><tr><td>CRRT Dose</t... | <table><tr><td>Data Elements</td></tr><tr><td>Dialysis catheter position</td></tr><tr><td>Dialysis catheter type (acute or tunneled)</td></tr><tr><td>Dialysis catheter manufacturer</td></tr><tr><td>Dialysis catheter size</td></tr><tr><td>Any need for catheter manipulation (e.g. repositioning, replacement)</td></tr><tr>... |
fabf18c090f7d349bebed00f083ee4644892745624b2651ae2edabd0415708bd.png | complex | <table><tr><td>Name</td><td>Description</td><td>Reference</td></tr><tr><td colspan="3">Integrative plasmid set with <i>URA3</i> selection marker flanked with direct repeats</td></tr><tr><td> pCfB126</td><td>pX-2-USER-URA3-DR</td><td>Mikkelsen <i>et al</i>. (2012)</td></tr><tr><td> pCfB127</td><td>pX-3-USER-URA3-DR</td>... | <table><tr><td>Name</td><td>Description</td><td>Reference</td></tr><tr><td colspan="3">Integrative plasmid set with URA3 selection marker flanked with direct repeats</td></tr><tr><td>pCfB126</td><td>pX-2-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB127</td><td>pX-3-USER-URA3-DR</td><td>Mikkelsen et... | <table><tr><td>Name</td><td>Description</td><td>Reference</td></tr><tr><td>B387</td><td>DR</td><td>al. (2012)</td></tr><tr><td>pCfB129</td><td>pXII-1-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB120</td><td>pXII-2-USER-URA3-DR</td><td>Mikkelsen et al. (2012)</td></tr><tr><td>pCfB130</td><td>pXII-4-... |
ff69e56110217af774f0516f687031ad5779c017a0c16065aeef5575dff1a650.png | simple | <table><tr><td></td><td>Specificity (%)</td><td>Sensitivity (%)</td><td>AUC</td><td>Confidence interval</td></tr><tr><td>Roc 1 (Both H&R scores >0)</td><td>83.3</td><td>61.1</td><td>72.3</td><td>63.61–82.22 %</td></tr><tr><td>Roc 2 (Both H&R scores >1)</td><td>81.4</td><td>67.8</td><td>75.3</td><td>... | <table><tr><td></td><td>Specificity (%)</td></tr><tr><td>Roc 1 (Both H&R scores >0)</td><td>83.3</td></tr><tr><td>Roc 2 (Both H&R scores >1)</td><td>81.4</td></tr><tr><td>Roc 3 (Both H&R scores >2)</td><td>77.5</td></tr><tr><td>Roc 4 (Both H&R scores >3)</td><td>71.8</td></tr></table> | <table><tr><td>Sensitivity (%)</td><td>AUC</td><td>Confidence interval</td></tr><tr><td>61.1</td><td>72.3</td><td>63.61–82.22 %</td></tr><tr><td>67.8</td><td>75.3</td><td>65.66–85.79 %</td></tr><tr><td>81.2</td><td>80.9</td><td>69.49–92.24 %</td></tr><tr><td>100.0</td><td>89.1</td><td>79.9 %–98.2 %</td></tr></table> |
5d9d0331778fe8389db8f27df0967019ccdda0ac8ccbb0dd43994a69f73d7e47.png | simple | <table><tr><td></td><td>PA-PRP (<i>n</i> = 11)</td><td>HA (<i>n</i> = 10)</td></tr><tr><td>Age, mean (SD) years</td><td>49.91 (13.72)</td><td>52.70 (10.30)</td></tr><tr><td>BMI, mean (SD) kg/m<sup>2</sup></td><td>27.92 (11.94)</td><td>30.87 (5.64)</td></tr><tr><td>Previous surgery, no. (%)</td><td>5 (45 %)</td><td>8 (8... | <table><tr><td></td></tr><tr><td>Age, mean (SD) years</td></tr><tr><td>BMI, mean (SD) kg/m2</td></tr><tr><td>Previous surgery, no. (%)</td></tr><tr><td>Gender (Male), no. (%)</td></tr><tr><td>Symptom duration, mean (SD) years</td></tr><tr><td>Cause of osteoarthritis, no.</td></tr><tr><td>Degeneration/unknown</td></tr><... | <table><tr><td>PA-PRP (n = 11)</td><td>HA (n = 10)</td></tr><tr><td>49.91 (13.72)</td><td>52.70 (10.30)</td></tr><tr><td>27.92 (11.94)</td><td>30.87 (5.64)</td></tr><tr><td>5 (45 %)</td><td>8 (80 %)</td></tr><tr><td>8 (72.73 %)</td><td>7 (70 %)</td></tr><tr><td>8.50 (4.95)</td><td>15 (7.07)</td></tr><tr><td></td><td></... |
59e466818280b4311fdf06afb0e03baddd579f9b12960abd754533c280aec613.png | complex | <table><tr><td colspan="2"></td><td>AML(n=11)</td><td>ALL(n=9)</td><td>MM(n=26)</td><td>NHL(n=6)</td><td>HL(n=12)</td><td>P value</td></tr><tr><td colspan="2">IL-6 (pg/mL)</td><td>95.10(55.10-140.90)</td><td>89.90 (61.90-690)</td><td>91.25(4.5-640)</td><td>68.10(33-152.9)</td><td>72.70(32-530)</td><td>0.25</td></tr><tr... | <table><tr><td colspan="2"></td><td>AML(n=11)</td><td>ALL(n=9)</td><td>MM(n=26)</td></tr><tr><td colspan="2">IL-6 (pg/mL)</td><td>95.10(55.10-140.90)</td><td>89.90 (61.90-690)</td><td>91.25(4.5-640)</td></tr><tr><td>IL-10 (pg/mL)</td><td colspan="2">86.20(68.50-640)</td><td>75.90(26-133.9)</td><td>87.75(41.40-588)</td>... | <table><tr><td>NHL(n=6)</td><td>HL(n=12)</td><td>P value</td></tr><tr><td>68.10(33-152.9)</td><td>72.70(32-530)</td><td>0.25</td></tr><tr><td>93.86(55-112)</td><td>86.05(58.20-215)</td><td>0.25</td></tr><tr><td>7(3-75)</td><td>3(3-75)</td><td>0.07</td></tr><tr><td>0.84(0.29-1.60)</td><td>0.76(0.22 -5.22)</td><td>0.21</... |
225a8efed3cedc97320fc1821a74af5639218c81ff4d316cc189ca6502a6658d.png | complex | <table><tr><td colspan="4">Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)</td></tr><tr><td>Physical</td><td>Psychological</td><td>Social</td><td>Spiritual</td></tr><tr><td>Biological markers</td><td>Absorption</td><td>Adjustment</td><td>Awareness</td></tr><tr><td>Disabili... | <table><tr><td colspan="4">Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)</td></tr><tr><td>Physical</td><td>Psychological</td><td>Social</td><td>Spiritual</td></tr><tr><td>Biological markers</td><td>Absorption</td><td>Adjustment</td><td>Awareness</td></tr><tr><td>Disabili... | <table><tr><td colspan="4">Holistic wellness/well-being (encompassing each of physical, psychological, social, spiritual)</td></tr><tr><td colspan="4">Patient expectations</td></tr><tr><td colspan="4">Patient-practitioner relationship</td></tr><tr><td colspan="4">Practitioner attitudes towards integration</td></tr><tr>... |
72b5eba9cf53dcaab08a1d0a4b1f14806eadd15ee88613515fa36c2d563240ae.png | simple | <table><tr><td>Rotarix<sup>® </sup>label</td><td>"In the manufacturing process, porcine-derived materials are used.Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans."</td></tr><tr><td>RotaTeqTM label</td><td>"In the manufacturing process for RotaTeq, a porcine-d... | <table><tr><td>Rotarix® label</td><td>"In the manufacturing process, porcine-derived materials are used.Porcine circovirus type 1 (PCV-1) is present in Rotarix. PCV-1 is not known to cause disease in humans."</td></tr></table> | <table><tr><td>RotaTeqTM label</td><td>"In the manufacturing process for RotaTeq, a porcine-derived material is used. DNA from porcine circoviruses (PCV) 1 and 2 has been detected in RotaTeq. PCV-1 and PCV-2 are not known to cause disease in humans."</td></tr></table> |
289212ed4ab09b7fceea8003c095be736131097335e13f93fed46bc78fbdea1b.png | simple | <table><tr><td>Probe set ID</td><td>Gene Symbol</td><td>Gene Title</td><td>Fold Change in Apc<sup><i>fl</i>/<i>fl </i></sup>p53<sup>-/- </sup>v WT</td></tr><tr><td>1418368_at</td><td>Retnlb</td><td>resistin like beta</td><td>0.002</td></tr><tr><td>1422422_at</td><td>Defcr4</td><td>defensin related cryptdin 4</td><td>27... | <table><tr><td>Probe set ID</td><td>Gene Symbol</td><td>Gene Title</td></tr><tr><td>1418368_at</td><td>Retnlb</td><td>resistin like beta</td></tr><tr><td>1422422_at</td><td>Defcr4</td><td>defensin related cryptdin 4</td></tr><tr><td>1425221_at</td><td>Agr3</td><td>anterior gradient homolog 3 (Xenopus laevis)</td></tr><... | <table><tr><td>Fold Change in Apcfl/fl p53-/- v WT</td></tr><tr><td>0.002</td></tr><tr><td>27.73</td></tr><tr><td>27.20</td></tr><tr><td>17.82</td></tr><tr><td>8.12</td></tr><tr><td>30.91</td></tr><tr><td>25.82</td></tr><tr><td>8.60</td></tr><tr><td>9.67</td></tr><tr><td>12.11</td></tr><tr><td>13.83</td></tr><tr><td>19... |
e952de5166425ac9f132bbdcf30b8ae41e4dd18868ab12534f330e3e2c2e49ef.png | simple | <table><tr><td>Acridine orange</td><td>A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.</td></tr><tr><td>Acriflavine</td><td>3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acr... | <table><tr><td>Acridine orange</td><td>A cationic cytochemical stain specific for cell nuclei, especially DNA. It is used as a supravital stain and in fluorescence cytochemistry. It may cause mutations in microorganisms.</td></tr><tr><td>Acriflavine</td><td>3,6-Diamino-10-methylacridinium chloride mixture. with 3,6-acr... | <table><tr><td>lavine</td><td>inly in wound dressings.</td></tr><tr><td>Tacrine</td><td>A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous sys... |
5f1044d6b74f43c39b13e351f5842198f3e5c14ad8b979ee29a55d2298c59cd0.png | simple | <table><tr><td>Loading of MWCNT (wt%)</td><td>Tg by DMA (°C)</td><td>CTE by TMA (×10<sup>−6</sup> K<sup>−1</sup>)</td></tr><tr><td>Control</td><td>161 ± 0.3</td><td>85 ± 0.3</td></tr><tr><td>0.1 </td><td>160 ± 0.1</td><td>89 ± 0.9</td></tr><tr><td>0.25 </td><td>162 ± 0.3</... | <table><tr><td>Loading of MWCNT (wt%)</td><td>Tg by DMA (°C)</td><td>CTE by TMA (×10−6 K−1)</td></tr><tr><td>Control</td><td>161 ± 0.3</td><td>85 ± 0.3</td></tr><tr><td>0.1</td><td>160 ± 0.1</td><td>89 ± 0.9</td></tr><tr><td>0.25</td><td>162 ± 0.3</td><td>90 ± 1.2</td></tr><tr><td>0.4</td><td>163 ± 0.4</td><td>87 ± 1.4... | <table><tr><td>0.5</td><td> 2.2</td><td>9</td></tr><tr><td>0.75</td><td>161 ± 0.9</td><td>87 ± 0.3</td></tr></table> |
d14421206be65684df13611af7db92daa89f4d7c2a825e03031da99a0c2beb07.png | simple | <table><tr><td> </td><td>Drug(s) resistant to</td><td>Typical diseases</td></tr><tr><td>Name of Bacterium</td><td> </td><td> </td></tr><tr><td> <i>Escherichia coli </i> </td><td>Cephalosporins and fluoroquinolones</td><td>Urinary tract infections and blood stream infections </td></tr><tr><td> <i>Klebsiella pneumoniae <... | <table><tr><td></td><td>Drug(s) resistant to</td><td>Typical diseases</td></tr><tr><td>Name of Bacterium</td><td></td><td></td></tr><tr><td>Escherichia coli</td><td>Cephalosporins and fluoroquinolones</td><td>Urinary tract infections and blood stream infections</td></tr><tr><td>Klebsiella pneumoniae</td><td>Cephalospor... | <table><tr><td>Name of Parasite</td><td></td><td></td></tr><tr><td>Plasmodia spp.</td><td>Chloroquine, artemisinin, and atovaquone [25]</td><td>Malaria</td></tr><tr><td>Leishmania spp.</td><td>Pentavalent antimonials, miltefosine, paromomycin, and amphotericin B [13, 14]</td><td>Leishmaniasis</td></tr><tr><td>Schistoso... |
813222bf4a6f7c538aca063fc60e7114a47efa100e479358e333891134f8a78c.png | simple | <table><tr><td> </td><td>Frequency</td><td>Percentage</td></tr><tr><td>Aetiology</td><td> </td><td> </td></tr><tr><td> Unknown</td><td>294</td><td>66.2%</td></tr><tr><td> Stone</td><td>44</td><td>9.9%</td></tr><tr><td> Nephrotic</td><td>22</td><td>5.0%</td></tr><tr><td> Glomerulonephritis (nephritic)</td><td>22</td><td... | <table><tr><td></td><td>Frequency</td><td>Percentage</td></tr><tr><td>Aetiology</td><td></td><td></td></tr><tr><td>Unknown</td><td>294</td><td>66.2%</td></tr><tr><td>Stone</td><td>44</td><td>9.9%</td></tr><tr><td>Nephrotic</td><td>22</td><td>5.0%</td></tr><tr><td>Glomerulonephritis (nephritic)</td><td>22</td><td>5.0%</... | <table><tr><td></td><td>Frequency</td><td>Percentage</td></tr><tr><td>VUR (vesicoureteral reflux)</td><td>3</td><td>.7%</td></tr><tr><td>Hepatitis B</td><td></td><td></td></tr><tr><td>Positive</td><td>11</td><td>2.5%</td></tr><tr><td>Negative</td><td>433</td><td>97.5%</td></tr><tr><td>Hepatitis C</td><td></td><td></td>... |
7bf5251b2c367da77d50e300d499b56ce2f8aa8bed7762c2e850e1ded17c4998.png | complex | <table><tr><td>Characteristic</td><td>LN group (n = 14)</td><td><i>P-value</i></td></tr><tr><td>Time since birth of first male child (yr)</td><td></td><td></td></tr><tr><td> 1 to 15 (n = 5)</td><td>9.25 ± 12.37</td><td>NS</td></tr><tr><td> >15 (n = 9)</td><td>5.5 ± 9.6</td><td></td></tr><tr><td>Time since ... | <table><tr><td>Characteristic</td><td>LN group (n = 14)</td><td>P-value</td></tr><tr><td>Time since birth of first male child (yr)</td><td></td><td></td></tr><tr><td>1 to 15 (n = 5)</td><td>9.25 ± 12.37</td><td>NS</td></tr><tr><td>>15 </td><td>5.</td><td></td></tr></table> | <table><tr><td>(n = 9)</td><td>5 ± 9.6</td><td></td></tr><tr><td>Time since SLE diagnosis (yr)</td><td></td><td></td></tr><tr><td>1 to 5 (n = 5)</td><td>10 ± 13.6</td><td rowspan="2">NS</td></tr><tr><td>>5 (n = 9)</td><td>5.08 ± 8</td></tr><tr><td>Number of male pregnancies</td><td></td><td></td></tr><tr><td>1 (n = 0)<... |
9baed7b578a3b099560318d20a979cd3ad4e327ecd867b02b67900f64b8b9397.png | simple | <table><tr><td>Methodology Followed</td><td>Start/End Point Needed</td><td>Tube Specific</td><td>No Automation</td><td>Seed Point Needed</td><td>time to detection</td><td>Surgical planning</td><td>Neuro-surgical planning</td><td>Arbitrary objects detection</td><td>Arbitrary image modality</td><td>Fine Vessel Accuracy</... | <table><tr><td>Methodology Followed</td><td>Start/End Point Needed</td><td>Tube Specific</td><td>No Automation</td><td>Seed Point Needed</td><td>time to detection</td><td>Surgical planning</td><td>Neuro-surgical planning</td><td>Arbitrary objects detection</td><td>Arbitrary image modality</td><td>Fine Vessel Accuracy</... | <table><tr><td>m2</td><td>y</td><td>y</td><td>y</td><td>n</td><td>gt</td><td>Y</td><td>y</td><td>y</td><td>y</td><td>gt</td><td>gt</td><td>lt</td><td>lt</td><td>eq</td></tr><tr><td>m3</td><td>y</td><td>y</td><td>n</td><td>n</td><td>gt</td><td>n</td><td>n</td><td>y</td><td>y</td><td>lt</td><td>eq</td><td>eq</td><td>lt</... |
127a6dbccac969ba74fb39a9375517577cc1d9f3415611ddd276ee25a2eda951.png | simple | <table><tr><td>No.</td><td>Activity reviewed</td><td>Activities confirmed (Pa)</td><td>Additional predicted activities (Pa<sup>a</sup>)</td></tr><tr><td>78</td><td>Antimicrobial antiviral antineoplastic</td><td>Antineoplastic (sarcoma) (0.413)</td><td>Atherosclerosis treatment (0.924)Genital warts treatment (0.600)</td... | <table><tr><td>No.</td><td>Activity reviewed</td><td>Activities confirmed (Pa)</td><td>Additional predicted activities (Paa)</td></tr><tr><td>78</td><td>Antimicrobial antiviral antineoplastic</td><td>Antineoplastic (sarcoma) (0.413)</td><td>Atherosclerosis treatment (0.924)Genital warts treatment (0.600)</td></tr><tr><... | <table><tr><td>97</td><td>Antimicrobial antiviral antineoplastic</td><td>Glycopeptide-like antibiotic (0.713)Antineoplastic (0.547)Antibacterial (0.424)</td><td>Analgesic (0.641)</td></tr></table> |
5b2253cea59e0eac5ee35f21cacc39a2b3a6bc53194e299103045b5a572f69b7.png | complex | <table><tr><td>Mobile phase</td><td>Relation</td><td>Volume (mL)</td><td>Fractions</td><td>Residue (mg)</td></tr><tr><td>Dichloromethane</td><td>100%</td><td>500</td><td>F4.3.1</td><td>0.4</td></tr><tr><td rowspan="3">Dichloromethane : ethyl acetate</td><td rowspan="3">90 : 10</td><td rowspan="3">500</td><td>F4.3.2</td... | <table><tr><td>Mobile phase</td><td>Relation</td><td>Volume (mL)</td><td>Fractions</td><td>Residue (mg)</td></tr><tr><td>Dichloromethane</td><td>100%</td><td>500</td><td>F4.3.1</td><td>0.4</td></tr><tr><td>Dichloromethane : ethyl acetate</td><td>90 : 10</td><td>500</td><td>F4.3.2</td><td>3</td></tr></table> | <table><tr><td rowspan="2">Dichloromethane : ethyl acetate</td><td rowspan="2">90 : 10</td><td rowspan="2">500</td><td>F4.3.3</td><td>59</td></tr><tr><td>F4.3.4</td><td>91</td></tr><tr><td rowspan="2">Dichloromethane : ethyl acetate</td><td rowspan="2">80 : 20</td><td rowspan="2">500</td><td>F4.3.5</td><td>256</td></tr... |
6d7fc47657d18d6bef2e443081c9f96a97a49071789360de652b4e2b97441bac.png | complex | <table><tr><td rowspan="3">Patient</td><td>F<sub>p</sub></td><td>v<sub>e</sub>*</td><td>v<sub>p</sub></td><td>PS</td><td>SUV*</td><td>Cellularity</td><td>Tumor</td></tr><tr><td>(mL.min<sup>−1</sup>.100g<sup>−1</sup>)</td><td>(%)</td><td>(%)</td><td>(mL.min<sup>−1</sup>.100g<sup>−1</sup>)</td><td... | <table><tr><td rowspan="3">Patient</td><td>Fp</td><td>ve*</td><td>vp</td><td>PS</td><td>SUV*</td><td>Cellularity</td><td>Tumor</td><td rowspan="2"></td></tr><tr><td>(mL.min−1.100g−1)</td><td>(%)</td><td>(%)</td><td>(mL.min−1.100g−1)</td><td></td><td>(%)</td><td>localization, staging</td></tr><tr><td colspan="8">Pretrea... | <table><tr><td>11</td><td>75.9</td><td>77.6</td><td>14.6</td><td>44.1</td><td>3.9</td><td>35</td><td></td><td rowspan="5"></td></tr><tr><td>12</td><td>184.0</td><td>47.4</td><td>8.9</td><td>33.8</td><td>3.4</td><td>22</td><td></td></tr><tr><td>13***</td><td>131.2</td><td>46.1</td><td>9.9</td><td>60.7</td><td>6.0</td><t... |
c3eb3f42444e4a5d5f647e5e83cef3d04eca96bc2ca19027cdf607282dc9ffec.png | simple | <table><tr><td></td><td>B</td><td>S.E.</td><td>Wald</td><td>df</td><td>Sig.</td><td>Exp(B)</td></tr><tr><td>TG</td><td>−0.634</td><td>0.402</td><td>2.489</td><td>1</td><td>0.115</td><td>0.530</td></tr><tr><td>Chol</td><td>0.511</td><td>0.825</td><td>0.384</td><td>1</td><td>0.536</td><td>1.667</td></tr><tr><td>LDL... | <table><tr><td></td><td>B</td><td>S.E.</td><td>Wald</td><td>df</td><td>Sig.</td><td>Exp(B)</td></tr><tr><td>TG</td><td>−0.634</td><td>0.402</td><td>2.489</td><td>1</td><td>0.115</td><td>0.530</td></tr><tr><td>Chol</td><td>0.511</td><td>0.825</td><td>0.384</td><td>1</td><td>0.536</td><td>1.667</td></tr><tr><td>LDL</td><... | <table><tr><td></td><td>B</td><td>S.E.</td><td>Wald</td><td>df</td><td>Sig.</td><td>Exp(B)</td></tr><tr><td>ApoB</td><td>−1.004</td><td>2.411</td><td>0.173</td><td>1</td><td>0.677</td><td>0.366</td></tr><tr><td>Constant</td><td>3.639</td><td>1.575</td><td>5.335</td><td>1</td><td>0.021</td><td>38.052</td></tr></table> |
06a8b9f21b315d93b99c4c8cc85784335e0c9e796fd7e361acc34557cfbfb23b.png | complex | <table><tr><td></td><td>Total (N)</td><td>N of Death</td><td>Median survival (months)*</td><td>Mean survival (months)</td><td><i>P</i> value</td></tr><tr><td colspan="6">Oct-4</td></tr><tr><td>Positive</td><td>58</td><td>26</td><td>43</td><td>45.1</td><td>0.022</td></tr><tr><td>Negative</td><td>36</td><td>8</td><td>*</... | <table><tr><td></td><td>Total (N)</td><td>N of Death</td><td>Median survival (months)*</td><td>Mean survival (months)</td><td>P value</td></tr><tr><td colspan="6">Oct-4</td></tr><tr><td>Positive</td><td>58</td><td>26</td><td>43</td><td>45.1</td><td>0.022</td></tr><tr><td>Negative</td><td>36</td><td>8</td><td>*</td><td>... | <table><tr><td></td><td>Total (N)</td><td>N of Death</td><td>Median survival (months)*</td><td>Mean survival (months)</td><td>P value</td></tr><tr><td colspan="6">Sox2</td></tr><tr><td>Positive</td><td>53</td><td>25</td><td>43</td><td>35.1</td><td>0.023</td></tr><tr><td>Negative</td><td>41</td><td>9</td><td>*</td><td>6... |
b2b2286ded5c376afb53197285e1cd028f5b30c1645eab01edcf80e9fa378f83.png | simple | <table><tr><td>Ref.</td><td>Textural features</td><td>Classifier</td><td>Accuracy</td></tr><tr><td>Mannivannan [23]</td><td>Four types of local features with CPM-BoW encoding</td><td>Ensemble SVMs</td><td>87.09%</td></tr><tr><td>Sansone [87]</td><td>Dense local descriptors with BoW encoding</td><td>SVM</td><td>83.64%</... | <table><tr><td>Ref.</td><td>Textural features</td><td>Classifier</td><td>Accuracy</td></tr><tr><td>Mannivannan [23]</td><td>Four types of local features with CPM-BoW encoding</td><td>Ensemble SVMs</td><td>87.09%</td></tr><tr><td>Sansone [87]</td><td>Dense local descriptors with BoW encoding</td><td>SVM</td><td>83.64%</... | <table><tr><td></td><td>ures</td><td>kNN</td><td>74.62%</td></tr><tr><td>Ponomarev [95]</td><td>Morphological and shape descriptors</td><td>SVM</td><td>73.53%</td></tr><tr><td>Roberts [90]</td><td>Wavelet transform-based features</td><td>SVM</td><td>66.99%</td></tr></table> |
08b2bbc68a9f49274003cad83b71203812102812744b6c5113f1f89f267565db.png | complex | <table><tr><td>Compounds</td><td>Signals</td><td>Assign of Signals</td><td>S/N</td><td>Signal Intensity</td><td>Quantitative Value (mg)</td></tr><tr><td rowspan="3">CTX3C</td><td>H</td><td>Hydroxyl group 44</td><td>81</td><td>0.40</td><td>0.4060 ± 0.0038</td></tr><tr><td>I</td><td>Olefin 2, 3, 13, 14, 18, 19, 23, ... | <table><tr><td>Compounds</td><td>Signals</td><td>Assign of Signals</td></tr><tr><td rowspan="3">CTX3C</td><td>H</td><td>Hydroxyl group 44</td></tr><tr><td>I</td><td>Olefin 2, 3, 13, 14, 18, 19, 23, 24</td></tr><tr><td>J</td><td>17-H</td></tr><tr><td rowspan="4">51OHCTX3C</td><td>K</td><td>17-H</td></tr><tr><td>L</td><t... | <table><tr><td>S/N</td><td>Signal Intensity</td><td>Quantitative Value (mg)</td></tr><tr><td>81</td><td>0.40</td><td>0.4060 ± 0.0038</td></tr><tr><td>-</td><td>-</td><td>0.4408 ± 0.0018</td></tr><tr><td>37</td><td>-</td><td>0.4243 ± 0.0067</td></tr><tr><td><10</td><td>0.013</td><td>0.0134 ± 0.0002</td></tr><tr><td>25</... |
d506ebb93445d098d14658c8ddd82b94868305765ca7d60a1fb2b653ecb13806.png | complex | <table><tr><td rowspan="2">Termb</td><td rowspan="2">KEGG pathway</td><td rowspan="2">Countc</td><td rowspan="2">%d</td><td colspan="2">Detected proteome backgrounde</td><td colspan="3">Entire proteome backgroundf</td></tr><tr><td><i>P</i>‐value</td><td>Fold enrichment</td><td><i>P</i>‐value</td><td>Fold en... | <table><tr><td rowspan="2">Termb</td><td rowspan="2">KEGG pathway</td><td rowspan="2">Countc</td><td rowspan="2">%d</td><td colspan="2">Detected proteome backgrounde</td><td colspan="3">Entire proteome backgroundf</td></tr><tr><td>P‐value</td><td>Fold enrichment</td><td>P‐value</td><td>Fold enrichment</td><td>Bonferron... | <table><tr><td>cgl00020</td><td>Citrate cycle (TCA cycle)</td><td>15</td><td>4.6</td><td>4.98E‐06</td><td>2.9</td><td>2.59E‐12</td><td>9.3</td><td>4.02E‐10</td></tr><tr><td>cgl00970</td><td>Aminoacyl‐tRNA biosynthesis</td><td>15</td><td>4.6</td><td>0.00 579</td><td>1.9</td><td>1.03E‐09</td><td>7.0</td><td>1.59E‐07</td>... |
55a841e20984576146e5de59e6eced46d8461f998c1e4edf1014b369fc2a55f4.png | simple | <table><tr><td></td><td>CSX (−)MetX (−)(N = 39)</td><td>CSX (+)MetX (−)(N = 35)</td><td>CSX (−)MetX (+)(N = 15)</td><td>CSX (+)MetX (+)(N = 24)</td><td><i>p</i><sup>a</sup></td><td><i>p</i><sup>b</sup></td></tr><tr><td>Adiponectin (μg/mL)</td><td>12.3 (7.0, 18.9)</td><td>3.4 (2.3, 7.2)</td>... | <table><tr><td></td><td>CSX (−)MetX (−)(N = 39)</td><td>CSX (+)MetX (−)(N = 35)</td><td>CSX (−)MetX (+)(N = 15)</td><td>CSX (+)MetX (+)(N = 24)</td><td>pa</td><td>pb</td></tr></table> | <table><tr><td>Adiponectin (μg/mL)</td><td>12.3 (7.0, 18.9)</td><td>3.4 (2.3, 7.2)</td><td>4.0 (2.0, 9.1)</td><td>2.8 (1.7, 7.7)</td><td><0.001</td><td><0.001</td></tr><tr><td>Leptin (ng/mL)</td><td>3.3 (1.3, 8.1)</td><td>5.1 (3.1, 11.0)</td><td>8.1 (5.1, 18.5)</td><td>8.7 (6.3, 17.4)</td><td><0.001</td><td><0.001</td>... |
bb89c69d2112174cd59d8587281855b89c5007293bb8d73f7e4f4147faa75ded.png | simple | <table><tr><td>The 4 ALSI factors</td><td>Number of Questions</td><td>Mean</td><td>Mean as % of Max.</td><td>SEM</td><td>Cronbach’s α</td></tr><tr><td>Deep approach</td><td>6 Questions</td><td>19.84</td><td>66.10</td><td>0.22</td><td>0.71</td></tr><tr><td>Surface approach</td><td>4 Questions</td><td>9.57</td... | <table><tr><td>The 4 ALSI factors</td><td>Number of Questions</td><td>Mean</td><td>Mean as % of Max.</td></tr><tr><td>Deep approach</td><td>6 Questions</td><td>19.84</td><td>66.10</td></tr><tr><td>Surface approach</td><td>4 Questions</td><td>9.57</td><td>47.85</td></tr><tr><td>Effort management /Organised studying</td>... | <table><tr><td>SEM</td><td>Cronbach’s α</td></tr><tr><td>0.22</td><td>0.71</td></tr><tr><td>0.15</td><td>0.64</td></tr><tr><td>0.18</td><td>0.74</td></tr><tr><td>0.15</td><td>0.58</td></tr></table> |
132368b04047a1d11eb2dd8034647ea483620af3299315e890532ca786609115.png | simple | <table><tr><td>Variable</td><td>RR (CI 95%)</td><td>p value*</td></tr><tr><td>Diabetes mellitus</td><td>1.3 (0.8–2)</td><td>0.2</td></tr><tr><td>Hepatopathy</td><td>4 (2.7–5.9)</td><td>< 0.001</td></tr><tr><td>Exposure to chemotherapy</td><td>1.6 (0.9–2.7)</td><td>0.1</td></tr></table> | <table><tr><td>Variable</td><td>RR (CI 95%)</td><td>p value*</td></tr><tr><td>Diabetes mellitus</td><td>1.3 (0.8–2)</td><td>0.2</td></tr><tr><td>Hepatopathy</td><td>4 (2.7–5.9)</td><td>< 0.001</td></tr></table> | <table><tr><td>Exposure to chemotherapy</td><td>1.6 (0.9–2.7)</td><td>0.1</td></tr></table> |
f5331a02505f54a43de4622f247f055b1678806add1df79c687db0f7aa51ae64.png | simple | <table><tr><td></td><td>Energy intake (kcal/day) B (95 %-CI)</td><td>Standard. Beta (95 %-CI)</td><td><i>P</i>-value</td><td>Satiety Response (score) B (95 %-CI)</td><td>Standard. Beta (95 %-CI)</td><td><i>P</i>-value</td></tr><tr><td>Weight</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Birth ... | <table><tr><td></td><td>Energy intake (kcal/day) B (95 %-CI)</td><td>Standard. Beta (95 %-CI)</td><td>P-value</td><td>Satiety Response (score) B (95 %-CI)</td><td>Standard. Beta (95 %-CI)</td><td>P-value</td></tr></table> | <table><tr><td>Weight</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Birth weight</td><td>−7.1 (−30.9; 16.7)</td><td>−0.02 (−0.09; 0.05)</td><td>0.56</td><td>−0.01 (−0.04; 0.02)</td><td>−0.02 (−0.08; 0.04)</td><td>0.51</td></tr><tr><td>Conditional weight 0–1 month</td><td>4.5 (−16.1; 25.2)</td><... |
9e30a721f646b323a0310b456870c6c559b584f30d52ef7a23e5293336f8733c.png | complex | <table><tr><td>Gene name</td><td colspan="2">N and D</td><td colspan="2">Medium N</td><td colspan="2">Medium D</td></tr><tr><td></td><td>Stability value*</td><td>SE</td><td>Stability value*</td><td>SE</td><td>Stability value*</td><td>SE</td></tr><tr><td>RPLPO</td><td>0.093</td><td>0.069</td><td>0.071</td><td>0.079</td>... | <table><tr><td>Gene name</td><td colspan="2">N and D</td><td colspan="2">Medium N</td><td colspan="2">Medium D</td></tr></table> | <table><tr><td></td><td>Stability value*</td><td>SE</td><td>Stability value*</td><td>SE</td><td>Stability value*</td><td>SE</td></tr><tr><td>RPLPO</td><td>0.093</td><td>0.069</td><td>0.071</td><td>0.079</td><td>0.050</td><td>0.135</td></tr><tr><td>TBP</td><td>0.109</td><td>0.065</td><td>0.100</td><td>0.072</td><td>0.05... |
1abddc2735253053b50aef49a18ab089f299b549ceaae1c7cb0248b218ada579.png | simple | <table><tr><td>Variable</td><td>Category</td><td>OR</td><td>95% CI</td></tr><tr><td>Age (ref: < 50 years)</td><td>> 50 years</td><td>0.49</td><td>0.09, 2.61</td></tr><tr><td>Gender (ref: male)</td><td>Female</td><td>0.52</td><td>0.11, 2.61</td></tr><tr><td>Albumin (ref: > 3.5)</td><td>≤3.5</td><td>16.3</... | <table><tr><td>Variable</td><td>Category</td><td>OR</td><td>95% CI</td></tr><tr><td>Age (ref: < 50 years)</td><td>> 50 years</td><td>0.49</td><td>0.09, 2.61</td></tr><tr><td>Gender (ref: male)</td><td>Female</td><td>0.52</td><td>0.11, 2.61</td></tr></table> | <table><tr><td>Albumin (ref: > 3.5)</td><td>≤3.5</td><td>16.3</td><td>1.14, 234.6</td></tr><tr><td>ASA class (ref: 1-2)</td><td>> 2</td><td>6.67</td><td>1.22, 33.34</td></tr><tr><td>Charlson score (re: = 0)</td><td>1-2</td><td>0.59</td><td>0.07, 5.08</td></tr><tr><td></td><td>3 and above</td><td>3.5</td><td>0.26, 46.3<... |
edcc9139314e881cea9656bc959b19432d29f8117f4d2013dec47ef7ce65dd01.png | simple | <table><tr><td></td><td>Serotonin</td><td>RANKL</td><td>P1NP</td><td>CTX</td></tr><tr><td>OVX+Saline versus SHAM+Saline</td><td>34.8% <sup>###</sup></td><td>77.6% <sup>###</sup></td><td>106% <sup>###</sup></td><td>74.4% <sup>###</sup></td></tr><tr><td>OVX+WBV versus SHAM+Saline</td><td>4.9%</td><td>4.6%</td><td>0.1%</t... | <table><tr><td></td><td>Serotonin</td><td>RANKL</td><td>P1NP</td><td>CTX</td></tr><tr><td>OVX+Saline versus SHAM+Saline</td><td>34.8% ###</td><td>77.6% ###</td><td>106% ###</td><td>74.4% ###</td></tr><tr><td>OVX+WBV versus SHAM+Saline</td><td>4.9%</td><td>4.6%</td><td>0.1%</td><td>42.7% ###</td></tr><tr><td>OVX+ALN ver... | <table><tr><td></td><td>Serotonin</td><td>RANKL</td><td>P1NP</td><td>CTX</td></tr><tr><td>OVX+WBV versus OVX+Saline</td><td>-22.2% ***</td><td>-41.1% ***</td><td>-51.4% ***</td><td>-18.2% **</td></tr><tr><td>OVX+ALN versus OVX+Saline</td><td>-3.3%</td><td>-43.0% ***</td><td>-54.4% ***</td><td>-19.3% **</td></tr><tr><td... |
788d34b4581b0a2dfada0f4d8cfc8a48ec2f9c3e82b4b080b0fbb75b1b6d743a.png | complex | <table><tr><td>Item</td><td colspan="4">Treatment<sup>b</sup></td><td rowspan="2">Pooled SEM</td><td colspan="3">Contrast<sup>c</sup></td></tr><tr><td></td><td>Control</td><td>LPS</td><td>LPS + Low GLP-2</td><td>LPS + High GLP-2</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Duodenum, g</td><td>17.8</td><td>15.2</td><t... | <table><tr><td>Item</td><td colspan="4">Treatmentb</td><td rowspan="2">Pooled SEM</td><td colspan="3">Contrastc</td></tr><tr><td></td><td>Control</td><td>LPS</td><td>LPS + Low GLP-2</td><td>LPS + High GLP-2</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Duodenum, g</td><td>17.8</td><td>15.2</td><td>17.4</td><td>17.9</t... | <table><tr><td>Item</td><td colspan="4">Treatmentb</td><td rowspan="2">Pooled SEM</td><td colspan="3">Contrastc</td></tr><tr><td></td><td>Control</td><td>LPS</td><td>LPS + Low GLP-2</td><td>LPS + High GLP-2</td><td>1</td><td>2</td><td>3</td></tr><tr><td>Ileum, g</td><td>43.8</td><td>38.5</td><td>42.2</td><td>47.1</td><... |
f06fb25db39405d05c4dd3e292efb064cf7ca59d3379bbef96543535f71ead8d.png | simple | <table><tr><td>SCD incidence rates per 100.000 person years</td><td>All</td><td>Men</td><td>Women</td><td>Incidence rate ratio</td><td><i>p</i>-value</td></tr><tr><td>1–35 years</td><td>2.7 (2.5–2.9)</td><td>3.6 (3.2–3.9)</td><td>1.8 (1,5–2,0)</td><td>2.0 (1.7–2.4)</td><td><0.01</td></t... | <table><tr><td>SCD incidence rates per 100.000 person years</td><td>All</td><td>Men</td><td>Women</td><td>Incidence rate ratio</td><td>p-value</td></tr><tr><td>1–35 years</td><td>2.7 (2.5–2.9)</td><td>3.6 (3.2–3.9)</td><td>1.8 (1,5–2,0)</td><td>2.0 (1.7–2.4)</td><td><0.01</td></tr><tr><td>1–18 years</td><td>1.0 (0.9–1.... | <table><tr><td>SCD incidence rates per 100.000 person years</td><td>All</td><td>Men</td><td>Women</td><td>Incidence rate ratio</td><td>p-value</td></tr><tr><td>19–35 years</td><td>4.4 (3.9–4.8)</td><td>5.9 (5.3–6.5)</td><td>2.8 (2.4–3.2)</td><td>2.1 (1.8–2.6)</td><td><0.01</td></tr></table> |
6b256f1a4d915ae71405933c6977941efe21ea3ebf9d9433464b38f2fcc5354e.png | simple | <table><tr><td>Parameter</td><td>Healthy donors</td><td>RCC patients</td><td>Patients < pT3</td><td>Patients ≥ pT3</td></tr><tr><td>Number of leukocytes</td><td>6,260 ± 310</td><td>7,005 ± 350</td><td>6,500 ± 402</td><td>8,340 ± 563</td></tr><tr><td>Granulocytes</td><td>4,227 ± 310</td... | <table><tr><td>Parameter</td><td>Healthy donors</td><td>RCC patients</td><td>Patients < pT3</td><td>Patients ≥ pT3</td></tr><tr><td>Number of leukocytes</td><td>6,260 ± 310</td><td>7,005 ± 350</td><td>6,500 ± 402</td><td>8,340 ± 563</td></tr><tr><td>Granulocytes</td><td>4,227 ± 310</td><td>5,103 ± 292</td><td>4,702 ± 3... | <table><tr><td>Monocytes</td><td>351 ± 39</td><td>375 ± 21</td><td>349 ± 22</td><td>441 ± 42</td></tr><tr><td>Dendritic cells (DC)</td><td>19 ± 2</td><td>16 ± 1</td><td>17 ± 1</td><td>13 ± 2</td></tr><tr><td>Lymphocytes</td><td>1,670 ± 111</td><td>1,566 ± 103</td><td>1,490 ± 110</td><td>1,760 ± 237</td></tr><tr><td>Neu... |
c4ebc42651d173584b975c000685161d0e12b12c65e5db9796d25faa3dd4d4db.png | simple | <table><tr><td>Rank</td><td>Active substance, drug formulation</td><td>No of prescriptions</td><td>Potentially harmful or known to be harmful excipients</td></tr><tr><td>1</td><td>Gentamicin, inj solution</td><td>200</td><td>Parabens, sodium metabisulphite</td></tr><tr><td>2</td><td>Simeticone, oral suspension</td><td>... | <table><tr><td>Rank</td></tr><tr><td>1</td></tr><tr><td>2</td></tr><tr><td>3</td></tr><tr><td>4</td></tr><tr><td>5</td></tr><tr><td>6</td></tr><tr><td>7</td></tr><tr><td>8</td></tr><tr><td>9</td></tr><tr><td>10</td></tr><tr><td>11</td></tr><tr><td>12</td></tr><tr><td>13</td></tr><tr><td>14</td></tr><tr><td>15</td></tr>... | <table><tr><td>Active substance, drug formulation</td><td>No of prescriptions</td><td>Potentially harmful or known to be harmful excipients</td></tr><tr><td>Gentamicin, inj solution</td><td>200</td><td>Parabens, sodium metabisulphite</td></tr><tr><td>Simeticone, oral suspension</td><td>108</td><td>Sodium benzoate, sacc... |
9556b403e6f798906059ef8d1c926afa1d31a212486272176732e0cfd9121638.png | complex | <table><tr><td></td><td colspan="2">Control</td><td colspan="2">Intervention</td><td></td></tr><tr><td></td><td>Preintervention</td><td>Postintervention</td><td>Preintervention</td><td>Postintervention</td><td>p Value</td></tr><tr><td>NOTECHS</td><td>72.09 (3.36)</td><td>70.09 (5.70)</td><td>71.62 (5.69)</td><td>75.44 ... | <table><tr><td></td><td colspan="2">Control</td><td colspan="2">Intervention</td><td></td></tr><tr><td></td><td>Preintervention</td><td>Postintervention</td><td>Preintervention</td><td>Postintervention</td><td>p Value</td></tr><tr><td>NOTECHS</td><td>72.09 (3.36)</td><td>70.09 (5.70)</td><td>71.62 (5.69)</td><td>75.44 ... | <table><tr><td></td><td colspan="2">Control</td><td colspan="2">Intervention</td><td></td></tr><tr><td></td><td>Preintervention</td><td>Postintervention</td><td>Preintervention</td><td>Postintervention</td><td>p Value</td></tr><tr><td>WHO S/O attempted, n (%)</td><td>0/11 (0)</td><td>0/10 (0)</td><td>2/26 (8)</td><td>7... |
67138aa4ae97959a3c628b1cfd9c4a3d30dc8acc9f91d1533099a84b82f631ba.png | complex | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose (mg/kg b.w.)</td><td colspan="5">Thickness of rat paw (cm)</td></tr><tr><td><i>T</i><sub>1 h</sub></td><td><i>T</i><sub>2 h</sub></td><td><i>T</i><sub>3 h</sub></td><td><i>T</i><sub>4 h</sub></td><td><i>T</i><sub>5 h</sub></td></tr><tr><td>Control</td><td> <... | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose (mg/kg b.w.)</td><td colspan="5">Thickness of rat paw (cm)</td></tr><tr><td>T1 h</td><td>T2 h</td><td>T3 h</td><td>T4 h</td><td>T5 h</td></tr><tr><td>Control</td><td></td><td>3.21 ± 0.03</td><td>3.64 ± 0.04</td><td>3.95 ± 0.02</td><td>4.11 ± 0.03</td><td>4.0... | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose (mg/kg b.w.)</td><td colspan="5">Thickness of rat paw (cm)</td></tr><tr><td>T1 h</td><td>T2 h</td><td>T3 h</td><td>T4 h</td><td>T5 h</td></tr><tr><td>BRME</td><td>400</td><td>3.12 ± 0.04 (17.14)</td><td>3.29 ± 0.02*** (41.02)</td><td>3.41 ± 0.05*** (46.79)</... |
59e464547abae9d11cac4d0d131110b625730ebe65e28f6e17ab1a217636619a.png | simple | <table><tr><td>Risk factors</td><td>Incisional SSI (+)</td><td>Incisional SSI (−)</td><td>β</td><td>SE</td><td>Hazard ratio (95 % CI)</td><td><i>p</i> value</td></tr><tr><td>BMI (≥25/<25 kg/m<sup>2</sup>)</td><td>8/10</td><td>8/49</td><td>0.31</td><td>1.60</td><td>2.28 (0.57–9.04)</td><td>0.24... | <table><tr><td>Risk factors</td><td>Incisional SSI (+)</td><td>Incisional SSI (−)</td><td>β</td><td>SE</td><td>Hazard ratio (95 % CI)</td><td>p value</td></tr></table> | <table><tr><td>BMI (≥25/<25 kg/m2)</td><td>8/10</td><td>8/49</td><td>0.31</td><td>1.60</td><td>2.28 (0.57–9.04)</td><td>0.241</td></tr><tr><td>VFA (≥100/<100 cm2)</td><td>12/6</td><td>14/43</td><td>0.38</td><td>2.86</td><td>4.32 (1.18–15.80)</td><td>0.027</td></tr></table> |
69d301de30762a8419db361e9e5092876d8c084114f6efe20e762c1e3d9bf2e9.png | complex | <table><tr><td></td><td>HV</td><td>NU</td><td>P values</td></tr><tr><td>n</td><td>35</td><td>33</td><td></td></tr><tr><td>Age [median (range)]</td><td>32 (23–78)</td><td>44 (18–78)</td><td>0.004</td></tr><tr><td>Sexe (% of female)</td><td>62 %</td><td>31 %</td><td>0.003</td></tr><tr><td>BMI [median (range)]... | <table><tr><td></td><td>HV</td><td>NU</td><td>P values</td></tr><tr><td>n</td><td>35</td><td>33</td><td></td></tr><tr><td>Age [median (range)]</td><td>32 (23–78)</td><td>44 (18–78)</td><td>0.004</td></tr><tr><td>Sexe (% of female)</td><td>62 %</td><td>31 %</td><td>0.003</td></tr><tr><td>BMI [median (range)]</td><td>26.... | <table><tr><td></td><td>HV</td><td>NU</td><td>P values</td></tr><tr><td>etes (NIDDM)</td><td>%</td><td>0 %</td><td>S</td></tr><tr><td>Pulmonary (asthma, emphysema, chronic pulmonary disease, pneumothorax)</td><td>0 %</td><td>24 %</td><td>0.006</td></tr><tr><td>Cardiovascular (ischaemia, deep vein thrombosis, infarction... |
35f9406ae5935c4b6cc5904c404cdc1de9addf8516c9cf2b6bfb73a179e8a596.png | complex | <table><tr><td></td><td colspan="2">Transitions</td><td colspan="4">Transversions</td></tr><tr><td></td><td>A/G</td><td>C/T</td><td>A/C</td><td>A/T</td><td>G/C</td><td>G/T</td></tr><tr><td>Numbers of allelic sites</td><td>1,466</td><td>1,430</td><td>463</td><td>463</td><td>423</td><td>473</td></tr><tr><td>Percentage of... | <table><tr><td></td><td colspan="2">Transitions</td><td colspan="4">Transversions</td></tr></table> | <table><tr><td></td><td>A/G</td><td>C/T</td><td>A/C</td><td>A/T</td><td>G/C</td><td>G/T</td></tr><tr><td>Numbers of allelic sites</td><td>1,466</td><td>1,430</td><td>463</td><td>463</td><td>423</td><td>473</td></tr><tr><td>Percentage of allelic sites</td><td>31.07%</td><td>30.31%</td><td>9.81%</td><td>9.81%</td><td>8.9... |
aa850fe472bfbf60bcf4e57d473162ba2a9c67b49ee5f75ff46eb8dfe40f0ce6.png | complex | <table><tr><td> </td><td colspan="3">IFN-beta clinical response</td><td>EDSS*</td><td>Relapses**</td></tr><tr><td> </td><td>N</td><td>Resp.</td><td>%</td><td> </td><td> </td></tr><tr><td>MHC2TA mRNA level decreased + HHV-6 in serum</td><td>21</td><td>5</td><td>23.8</td><td>1.5</td><td>1.2</td></tr><tr><td>MHC2TA mRNA l... | <table><tr><td></td><td colspan="3">IFN-beta clinical response</td><td>EDSS*</td><td>Relapses**</td></tr></table> | <table><tr><td></td><td>N</td><td>Resp.</td><td>%</td><td></td><td></td></tr><tr><td>MHC2TA mRNA level decreased + HHV-6 in serum</td><td>21</td><td>5</td><td>23.8</td><td>1.5</td><td>1.2</td></tr><tr><td>MHC2TA mRNA level increased without HHV-6 in serum</td><td>99</td><td>58</td><td>58.6</td><td>- 0.5</td><td>0.4</td... |
c4850cfccba48e02bb3fba4d49220f5fa18c45eb3491f609bc8fd68f0a9ec218.png | simple | <table><tr><td>SN</td><td>Age</td><td>Vaccine</td></tr><tr><td>1</td><td>Birth (0–11 Months)</td><td>BCG</td></tr><tr><td>2</td><td>Birth (as soon as possible within 14 days of life</td><td>OPV0</td></tr><tr><td>3</td><td>6 Weeks</td><td>Pentavalent 1, OPV1</td></tr><tr><td>4</td><td>10 Weeks</td><td>Pentavalent ... | <table><tr><td>SN</td><td>Age</td></tr><tr><td>1</td><td>Birth (0–11 Months)</td></tr><tr><td>2</td><td>Birth (as soon as possible within 14 days of life</td></tr><tr><td>3</td><td>6 Weeks</td></tr><tr><td>4</td><td>10 Weeks</td></tr><tr><td>5</td><td>14 Weeks</td></tr><tr><td>6</td><td>9 Months</td></tr><tr><td>7</td>... | <table><tr><td>Vaccine</td></tr><tr><td>BCG</td></tr><tr><td>OPV0</td></tr><tr><td>Pentavalent 1, OPV1</td></tr><tr><td>Pentavalent 2, OPV2</td></tr><tr><td>Pentavalent 3, OPV3</td></tr><tr><td>Measles, OPV4</td></tr><tr><td>Measles</td></tr></table> |
c681be127fe81a272982bf169938d65bb25c7102a73f5f99fbee9d3a885c90de.png | complex | <table><tr><td></td><td colspan="5">Northern California Family Cohort</td></tr><tr><td></td><td>Source population</td><td>Contacted</td><td>Tier I</td><td>Tier II</td><td>Tier III</td></tr><tr><td>Number of households</td><td>11,850</td><td>1,955</td><td>499</td><td>186</td><td>30</td></tr><tr><td>Age</td><td></td><td>... | <table><tr><td></td><td colspan="5">Northern California Family Cohort</td></tr><tr><td></td><td>Source population</td><td>Contacted</td><td>Tier I</td><td>Tier II</td><td>Tier III</td></tr><tr><td>Number of households</td><td>11,850</td><td>1,955</td><td>499</td><td>186</td><td>30</td></tr><tr><td>Age</td><td></td><td>... | <table><tr><td></td><td colspan="5">Northern California Family Cohort</td></tr><tr><td>years</td><td>17.7%</td><td>7%</td><td>6%</td><td>%</td><td>%</td></tr><tr><td>>16 years</td><td>15.4%</td><td>22.3%</td><td>30.7%</td><td>37.1%</td><td>40.0%</td></tr><tr><td>Race/ethnicityd</td><td></td><td>*b</td><td>*b</td><td></... |
0d35174e00a1d01a94cbea462c12edc9e0a0b817b05a89bce42110700e286caa.png | simple | <table><tr><td></td><td>2012</td><td>2013</td><td>2014</td></tr><tr><td>MTI Requests</td><td>44,970</td><td>42,919</td><td>87,549</td></tr><tr><td># Items processed</td><td>3,148,431</td><td>7,963,477</td><td>11,294,998</td></tr><tr><td>MeSH on demand requests</td><td>–</td><td>–</td><td>225,750</td></tr><t... | <table><tr><td></td><td>2012</td><td>2013</td><td>2014</td></tr><tr><td>MTI Requests</td><td>44,970</td><td>42,919</td><td>87,549</td></tr></table> | <table><tr><td></td><td>2012</td><td>2013</td><td>2014</td></tr><tr><td># Items processed</td><td>3,148,431</td><td>7,963,477</td><td>11,294,998</td></tr><tr><td>MeSH on demand requests</td><td>–</td><td>–</td><td>225,750</td></tr><tr><td># Different domains</td><td>118</td><td>124</td><td>147</td></tr></table> |
21870cbac63914dcf1b2b9ea84eb6dcf978b2abd2132a1423e43e17bdd611397.png | simple | <table><tr><td>Gene</td><td>Primer sequence</td><td></td><td>Base pairs</td><td>Source</td></tr><tr><td>18S</td><td>Forward sequence</td><td>TGG TCG CTC GCT CCT CTC C</td><td>360</td><td>NR_003286</td></tr><tr><td></td><td>Reverse sequence</td><td>CGC CTG CTG CCT TCC TTG G</td><td></td><td></td></tr><tr><td>αSMA</... | <table><tr><td>Gene</td><td>Primer sequence</td><td></td><td>Base pairs</td><td>Source</td></tr><tr><td>18S</td><td>Forward sequence</td><td>TGG TCG CTC GCT CCT CTC C</td><td>360</td><td>NR_003286</td></tr><tr><td></td><td>Reverse sequence</td><td>CGC CTG CTG CCT TCC TTG G</td><td></td><td></td></tr><tr><td>αSMA</td><t... | <table><tr><td>IL-1β</td><td>Forward sequence</td><td>GCC GAT GGT CCC AAT TAC AT</td><td>121</td><td>M26295</td></tr><tr><td></td><td>Reverse sequence</td><td>ACA AGA CCT GCC GGA AGC T</td><td></td><td></td></tr><tr><td>IL-6</td><td>Forward sequence</td><td>CCT GCC TGC TGA GAA TCA CTT</td><td>51</td><td>AF469048</td></... |
5cf9bc00a290054df126736c8a78894f68c17ff3dc9d362722128e861dfa5b38.png | simple | <table><tr><td>Exercise</td><td>Description</td></tr><tr><td>Exercise 1Relaxing</td><td>Diaphragmatic breathing and postural elements such as alignment of the midline.The patient is supine on a mat with flexed knees and arms along the chest.</td></tr><tr><td>Exercise 2Raising arm, opening and closing punches</td><td>Ly... | <table><tr><td>Exercise</td><td>Description</td></tr><tr><td>Exercise 1Relaxing</td><td>Diaphragmatic breathing and postural elements such as alignment of the midline.The patient is supine on a mat with flexed knees and arms along the chest.</td></tr><tr><td>Exercise 2Raising arm, opening and closing punches</td><td>Ly... | <table><tr><td>Exercise</td><td>Description</td></tr><tr><td>Exercise 13Bar</td><td>Sitting or standing, hold the bar (about 110 cm long). Bring the arms forward and upward at the elbows extended. Flex elbows and bring the bar behind the head. Return slowly to starting position. Repeat ten times.</td></tr><tr><td>Exerc... |
5c0c45e5ea914bf613388cc8d97959fd5ca7dbf5f824a9613ea9efbece97a336.png | simple | <table><tr><td>Plantation collaboration</td><td>I</td><td>II</td><td>III</td><td>IV</td><td>V</td><td>VI</td><td>VII</td></tr><tr><td>IRS/ITN re/treatment</td><td>PL in negotiation to cover; currently covered by MCP</td><td>PL in negotiation to cover; currently covered by MCP</td><td>PL in negotiation to cover; current... | <table><tr><td>Plantation collaboration</td><td>I</td><td>II</td><td>III</td><td>IV</td><td>V</td><td>VI</td><td>VII</td></tr></table> | <table><tr><td>IRS/ITN re/treatment</td><td>PL in negotiation to cover; currently covered by MCP</td><td>PL in negotiation to cover; currently covered by MCP</td><td>PL in negotiation to cover; currently covered by MCP</td><td>PL subcontracts out; MCP supervises activities</td><td>PL conducts, MCP supervises activities... |
a7e686a6efeef646b653deec2936d3b7e2bb62c3bbad635762bc375855d227e2.png | complex | <table><tr><td rowspan="3">Variables</td><td colspan="4">IHM</td></tr><tr><td colspan="2">Model 1</td><td colspan="2">Model 2</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td>Age</td><td>1.07</td><td>0.995–1.14</td><td>1.07</td><td>0.995–1.16</td></tr><tr><td>Sex</td><td>2.27</t... | <table><tr><td rowspan="3">Variables</td><td colspan="4">IHM</td></tr><tr><td colspan="2">Model 1</td><td colspan="2">Model 2</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td>Age</td><td>1.07</td><td>0.995–1.14</td><td>1.07</td><td>0.995–1.16</td></tr></table> | <table><tr><td>Sex</td><td>2.27</td><td>0.41–12.64</td><td>1.19</td><td>0.18–7.73</td></tr><tr><td>Cirrhosis</td><td>1.12</td><td>0.30–4.27</td><td>1.20</td><td>0.30–4.84</td></tr><tr><td>Treatment</td><td>1.05</td><td>0.29–3.88</td><td>1.16</td><td>0.30–4.47</td></tr><tr><td>MELD</td><td>1.02</td><td>0.96–1.09</td><td... |
8d739c0f12e21d59bc29fad54722bab1b95d60816787caa89cd913dd02ff95e6.png | simple | <table><tr><td>Characteristics</td><td>Median (Range)</td></tr><tr><td>Age, years</td><td>70 (55-85)</td></tr><tr><td>PSA, ng/ml</td><td>24.2 (2.6-269.6)</td></tr><tr><td>Hemoglobin, g/l</td><td>124 (69-156)</td></tr><tr><td>ALP, U/l</td><td>111 (47-2779)</td></tr><tr><td>LDH, U/l</td><td>208 (114-2467)</td></tr><tr><t... | <table><tr><td>Characteristics</td><td>Median (Range)</td></tr><tr><td>Age, years</td><td>70 (55-85)</td></tr><tr><td>PSA, ng/ml</td><td>24.2 (2.6-269.6)</td></tr><tr><td>Hemoglobin, g/l</td><td>124 (69-156)</td></tr><tr><td>ALP, U/l</td><td>111 (47-2779)</td></tr><tr><td>LDH, U/l</td><td>208 (114-2467)</td></tr><tr><t... | <table><tr><td>Characteristics</td><td>Median (Range)</td></tr><tr><td></td><td>)</td></tr><tr><td>Lung</td><td>4 (5.7)</td></tr><tr><td>Other soft tissue</td><td>5 (7.1)</td></tr></table> |
acee4e98ab8db7d1103a06e55c8a91d42189d9305546641e9bd70204c2997647.png | complex | <table><tr><td>Primer set</td><td>Primer 1</td><td>Primer 2</td><td>FAMTM Labelled Probe</td><td>VicTM Labelled Probe</td><td>Fluorescent Quencher</td><td>Anneal (1 minute)</td></tr><tr><td><i>TGFB1 </i>-800G>A</td><td>gctatcgcctgcacacagc</td><td>aggacagaagcggtcccat</td><td>tgcctccaacgtcaccaccatc</td><td>tctgcctccaa... | <table><tr><td>Primer set</td><td>Primer 1</td><td>Primer 2</td><td>FAMTM Labelled Probe</td><td>VicTM Labelled Probe</td><td>Fluorescent Quencher</td><td>Anneal (1 minute)</td></tr><tr><td>TGFB1 -800G>A</td><td>gctatcgcctgcacacagc</td><td>aggacagaagcggtcccat</td><td>tgcctccaacgtcaccaccatc</td><td>tctgcctccaacatcaccacc... | <table><tr><td>TGFB1 +869T>C</td><td>caccacaccagccctgttc</td><td>ccaggcgtcagcaccagta</td><td>agcagcggcagca</td><td>cagcagcagcagc</td><td>None</td><td>60°C</td></tr><tr><td>TGFB1 +915G>C</td><td colspan="4">Developed by Applied Biosystems (USA) as a Research and Development Kit</td><td>None</td><td>56°C</td></tr></table... |
fa28cc6aae2aced3e7c5962f9954a3a45ba9cdf914f08a0f2ee7f81530bf1d02.png | simple | <table><tr><td>Inclusion criteria</td><td>Exclusion criteria</td></tr><tr><td>At least 16 years old</td><td>Present fracture or other joint pathology/bone matrix pathology</td></tr><tr><td>Visited the ER within one week after a lateral ankle sprain</td><td>A diagnosed OCD after primary inclusion</td></tr><tr><td>Agreed... | <table><tr><td>Inclusion criteria</td></tr><tr><td>At least 16 years old</td></tr><tr><td>Visited the ER within one week after a lateral ankle sprain</td></tr><tr><td>Agreed with being approached for this study</td></tr><tr><td>Reported anterolateral ankle pain after an ankle sprain or ankle distortion</td></tr><tr><td... | <table><tr><td>Exclusion criteria</td></tr><tr><td>Present fracture or other joint pathology/bone matrix pathology</td></tr><tr><td>A diagnosed OCD after primary inclusion</td></tr><tr><td>Medial ankle instability</td></tr><tr><td>Previous ankle surgery</td></tr><tr><td>An unreliable radiograph due to the angle in whic... |
e30e44d8d2377c1929b573edc3dd4b0f09c62e7a622067b831c754a5ee6afeba.png | complex | <table><tr><td></td><td colspan="2">PAX8 staining N (%)</td><td rowspan="2"><i>P</i>-value<sup>†</sup></td></tr><tr><td>Clinical Feature</td><td>Low/Absent</td><td>Medium/High</td></tr><tr><td>Stage</td><td></td><td></td><td></td></tr><tr><td>1</td><td>17 (30)</td><td>39 (70)</td><td>0.013*</td></tr><tr><td>2</td... | <table><tr><td></td></tr><tr><td>Clinical Feature</td></tr><tr><td>Stage</td></tr><tr><td>1</td></tr><tr><td>2</td></tr><tr><td>3</td></tr><tr><td>4</td></tr><tr><td>Grade</td></tr><tr><td>G1</td></tr><tr><td>G2</td></tr><tr><td>G3</td></tr><tr><td>Residual Disease</td></tr><tr><td>Optimal debulking</td></tr><tr><td>Su... | <table><tr><td colspan="2">PAX8 staining N (%)</td><td rowspan="2">P-value†</td></tr><tr><td>Low/Absent</td><td>Medium/High</td></tr><tr><td></td><td></td><td></td></tr><tr><td>17 (30)</td><td>39 (70)</td><td>0.013*</td></tr><tr><td>6 (21)</td><td>22 (79)</td><td></td></tr><tr><td>16 (14)*</td><td>101 (86)*</td><td></t... |
8115e1519066d2a8c1d74ce2b7913a7703560ccfa16ca15e3084ec18d7e9d7dd.png | simple | <table><tr><td>Types of home visits</td><td>Influencing conditions and causes</td><td>Strategies to achieve “productive performance”</td><td>Consequences of “productive performance”</td></tr><tr><td>• Visits on demand• Periodic visits• Nursing home round• Visits based on ... | <table><tr><td>Types of home visits</td><td>Influencing conditions and causes</td><td>Strategies to achieve “productive performance”</td><td>Consequences of “productive performance”</td></tr></table> | <table><tr><td>• Visits on demand• Periodic visits• Nursing home round• Visits based on ad-hoc-decisions</td><td>• Nurse characteristics• Resident characteristics• Nursing home environment</td><td>Preparing strategies • Scheduling and planning • PreparingOn-site strategies • Gathering information • Seeking nurses ́ att... |
ff592f2b5d3a01c8a82cfc605598c7ed9abd75570e7a6a78e8e4fcc2b4d96896.png | complex | <table><tr><td>Criteria as provided in Figure 1</td><td>Median, days (range) No. (%)</td><td>≥0 days No. (%)</td><td>>0 days No. (%)</td><td>≤0 days No. (%)</td><td>= 0 days No. (%)</td><td><0 days No. (%)</td><td>Ref.</td></tr><tr><td colspan="8"><i>Lead times</i></td></tr><tr><td colspan="8"><i>4A A... | <table><tr><td>Criteria as provided in Figure 1</td><td>Median, days (range) No. (%)</td><td>≥0 days No. (%)</td><td>>0 days No. (%)</td><td>≤0 days No. (%)</td><td>= 0 days No. (%)</td><td><0 days No. (%)</td><td>Ref.</td></tr><tr><td colspan="8">Lead times</td></tr><tr><td colspan="8">4A All histological tumor types<... | <table><tr><td> al.†</td><td>48)</td><td>14 (47)</td><td>3)</td><td>3)</td><td>1 (3)</td><td>0</td><td></td></tr><tr><td>Criterion 1B, Tuxen et al.†</td><td>27 (0–257)</td><td>9 (30)</td><td>7 (23)</td><td>3 (10)</td><td>2 (7)</td><td>1 (3)</td><td>[7,20]</td></tr><tr><td>Criterion 1C, Tuxen et al.†</td><td>87 (0–356)<... |
f9b83d66e1d34bda0555aa6aa2f2f833e011d0a832b3ae8a076cd0ea166c6a9b.png | simple | <table><tr><td>Treatments</td><td><i>invH</i></td><td><i>hilA</i></td><td><i>hilD</i></td><td><i>sipA</i></td><td><i>sipB</i></td><td><i>sopB</i></td><td><i>spvB</i></td></tr><tr><td>SE Ctrl</td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup>a</sup></td><td>1 <sup... | <table><tr><td>Treatments</td><td>invH</td><td>hilA</td><td>hilD</td><td>sipA</td><td>sipB</td><td>sopB</td><td>spvB</td></tr><tr><td>SE Ctrl</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td></tr><tr><td>SE + LR</td><td>–1.85 ± 0.08 b</td><td>–4.58 ± 1.13 b–d</td><td>–2.90 ± 0.15 ... | <table><tr><td>SE + LP</td><td>–4.07± 0.84 a,b</td><td>–4.07 ± 0.38 b–d</td><td>–2.81 ± 0.28 b,c</td><td>–11.19± 0.36 d,e</td><td>–27.19 ± 0.66 i</td><td>–15.70± 0.54 e–g</td><td>–25.46 ± 0.91 h,i</td></tr><tr><td>ST Ctrl</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td><td>1 a</td></tr><tr><... |
42bb023c0f7fc6e44a38e21eabec35538491a4cc3cd871ea63b18551baf02d0b.png | complex | <table><tr><td></td><td>Instrument</td><td>Baseline (T0)</td><td>2 months (T1)</td><td>4 months (T2)</td><td>8 months (T3)</td><td>12 months (T4)</td></tr><tr><td colspan="7">Primary outcomes</td></tr><tr><td>Physical functioning</td><td>PCS of RAND-36</td><td>x</td><td>x</td><td>x</td><td></td><td>x</td></tr><tr><td>D... | <table><tr><td></td><td>Instrument</td><td>Baseline (T0)</td><td>2 months (T1)</td><td>4 months (T2)</td><td>8 months (T3)</td><td>12 months (T4)</td></tr><tr><td colspan="7">Primary outcomes</td></tr><tr><td>Physical functioning</td><td>PCS of RAND-36</td><td>x</td><td>x</td><td>x</td><td></td><td>x</td></tr><tr><td>D... | <table><tr><td></td><td>Instrument</td><td>Baseline (T0)</td><td>2 months (T1)</td><td>4 months (T2)</td><td>8 months (T3)</td><td>12 months (T4)</td></tr><tr><td colspan="7">Potential mediators</td></tr><tr><td>Health anxiety</td><td>Whitely Index</td><td>x</td><td>x</td><td>x</td><td></td><td></td></tr><tr><td>Illnes... |
9d99184cc09e58b5d4f6c1bffd6b2690308efa507749725946c7707e9775e1df.png | complex | <table><tr><td></td><td colspan="2">Sex</td><td><i>F</i></td><td><i>p</i></td></tr><tr><td></td><td>Male</td><td>Female</td><td></td><td></td></tr><tr><td>Left</td></tr><tr><td>Anterior</td><td>1202.93 (4.21)</td><td>1180.06 (3.77)</td><td>14.92</td><td>0.0001</td></tr><tr><td>Middle</td><td>2458.53 (10.52)</td><td>245... | <table><tr><td></td><td colspan="2">Sex</td></tr><tr><td></td><td>Male</td><td>Female</td></tr><tr><td>Left</td><td colspan="2"></td></tr><tr><td>Anterior</td><td>1202.93 (4.21)</td><td>1180.06 (3.77)</td></tr><tr><td>Middle</td><td>2458.53 (10.52)</td><td>2458.69 (9.43)</td></tr><tr><td>Posterior</td><td>585.90 (4.07)... | <table><tr><td>F</td><td>p</td></tr><tr><td></td><td></td></tr><tr><td colspan="2"></td></tr><tr><td>14.92</td><td>0.0001</td></tr><tr><td>0.0001</td><td>0.99</td></tr><tr><td>24.32</td><td>0.000001</td></tr><tr><td colspan="2"></td></tr><tr><td>13.44</td><td>0.0003</td></tr><tr><td>0.01</td><td>0.93</td></tr><tr><td>9... |
51e42e2da7c5e900bea78a05706a541a6aa7897b171a8abb1a83c7d1dd71807e.png | complex | <table><tr><td></td><td>Q1:50.8 g/day (46.3, 53.6)<sup>a</sup></td><td>Q2:59.6 g/day (57.8, 61.5)<sup>a</sup></td><td>Q3:68.0 g/day (65.7, 70.4)<sup>a</sup></td><td>Q4:81.6 g/day (76.3, 89.9)<sup>a</sup></td></tr><tr><td colspan="5">Demographic and lifestyle factors</td></tr><tr><td> N (cases)</td><td>2173 (146)</td><t... | <table><tr><td></td><td>Q1:50.8 g/day (46.3, 53.6)a</td><td>Q2:59.6 g/day (57.8, 61.5)a</td><td>Q3:68.0 g/day (65.7, 70.4)a</td><td>Q4:81.6 g/day (76.3, 89.9)a</td></tr><tr><td colspan="5">Demographic and lifestyle factors</td></tr><tr><td>N (cases)</td><td>2173 (146)</td><td>21,734 (128)</td><td>2173 (145)</td><td>217... | <table><tr><td>Coffee consumption (yes, %)</td><td>1.3</td><td>1.7</td><td>2.4</td><td>4.0</td></tr><tr><td>Alcohol consumption (yes, %)</td><td>20.9</td><td>17.3</td><td>20.7</td><td>22.2</td></tr><tr><td colspan="5">Daily nutrient intakes</td></tr><tr><td>Total energy (kcal/day)b</td><td>2277.1 ± 658.0</td><td>1976.1... |
5cb97a3f68e1a0cc22f2c40fc6d4905ee2ecc31f25a83fee3efb65a43c759818.png | complex | <table><tr><td>Characteristic</td><td>N = 981 (%)</td></tr><tr><td colspan="2">Demographics and Health Habits from Patient Survey</td></tr><tr><td>Age</td><td></td></tr><tr><td> 64–74 years</td><td>61</td></tr><tr><td> 75 + years</td><td>39</td></tr><tr><td>Race</td><td></td></tr><tr><td> Caucasian</td><td>92</td... | <table><tr><td>Characteristic</td><td>N = 981 (%)</td></tr><tr><td colspan="2">Demographics and Health Habits from Patient Survey</td></tr><tr><td>Age</td><td></td></tr><tr><td>64–74 years</td><td>61</td></tr><tr><td>75 + years</td><td>39</td></tr><tr><td>Race</td><td></td></tr><tr><td>Caucasian</td><td>92</td></tr><tr... | <table><tr><td>≥5</td><td>13</td></tr><tr><td>Visits to identified primary care providerb</td><td></td></tr><tr><td>0 – 25%</td><td>8</td></tr><tr><td>26 – 50%</td><td>12</td></tr><tr><td>51 – 75%</td><td>19</td></tr><tr><td>76 – 100%</td><td>62</td></tr><tr><td colspan="2">Preventive Health Service Usage from Medical ... |
fc9846bc858f4a482c3929d8a4d441038d517a69afa78ced87fa21214fa9ebd9.png | simple | <table><tr><td>References</td><td>Number of cases</td><td>Sex</td><td>Age (years)</td><td>Sites of lesion</td><td>Procedure</td><td>Recurrence</td></tr><tr><td>Verma and Paul [15]</td><td>1</td><td>F</td><td>39</td><td>Metacarpal</td><td>En bloc resection, autograft</td><td>No</td></tr><tr><td>Gebert <i>et al</i>. [16]... | <table><tr><td>References</td><td>Number of cases</td><td>Sex</td><td>Age (years)</td><td>Sites of lesion</td><td>Procedure</td><td>Recurrence</td></tr></table> | <table><tr><td>Verma and Paul [15]</td><td>1</td><td>F</td><td>39</td><td>Metacarpal</td><td>En bloc resection, autograft</td><td>No</td></tr><tr><td>Gebert et al. [16]</td><td>1</td><td>F</td><td>17</td><td>Radius</td><td>En bloc resection, autograft</td><td>No</td></tr><tr><td>Koskinen [17]</td><td>12</td><td>N/A</td... |
20b5b86746cde5b809a4da70bd9ddf99e93727f42f37185460efab52c6a52311.png | simple | <table><tr><td>Setup</td><td>AIC score</td><td>BIC score</td><td>HQC score</td><td>Prob. score</td></tr><tr><td>1000 individuals</td><td></td><td></td><td></td><td></td></tr><tr><td>1 mutation</td><td>0.0787 ± 0.118</td><td>0.0705 ± 0.111</td><td>0.068 ± 0.111</td><td>0.068 ± 0.103</td></tr><tr><td>... | <table><tr><td>Setup</td><td>AIC score</td><td>BIC score</td><td>HQC score</td><td>Prob. score</td></tr><tr><td>1000 individuals</td><td></td><td></td><td></td><td></td></tr><tr><td>1 mutation</td><td>0.07</td><td>0.0705 ± </td><td></td><td>0.068 ± 0.</td></tr></table> | <table><tr><td></td><td>87 ± 0.118</td><td>0.111</td><td>0.068 ± 0.111</td><td>103</td></tr><tr><td>2 mutations</td><td>0.061 ± 0.09</td><td>0.068 ± 0.113</td><td>0.059 ± 0.091</td><td>0.066 ± 0.103</td></tr><tr><td>200 individuals</td><td></td><td></td><td></td><td></td></tr><tr><td>1 mutation</td><td>0.235 ± 0.230</t... |
fe44a283fd48a66543f5b2c6562c2689fe1173e320cbe3fd7c71af0bd8d9f210.png | simple | <table><tr><td></td><td>Controls(<i>n</i> = 10)<i>n</i> (%)</td><td>Diabetes (<i>n</i> = 20) <i>n</i> (%)</td><td>New diabetes (<i>n</i> = 8) <i>n</i> (%)</td><td><i>p</i></td></tr><tr><td>MIBP</td><td>9 (90)</td><td>15 (75)</td><td>7 (88)</td><td>0.640</td></tr><tr><td>MBP</td><td>2 (20)</td><td>3 (15)</td><td>3 (38)<... | <table><tr><td></td><td>Controls(n = 10)n (%)</td><td>Diabetes (n = 20) n (%)</td><td>New diabetes (n = 8) n (%)</td><td>p</td></tr><tr><td>MIBP</td><td>9 (90)</td><td>15 (75)</td><td>7 (88)</td><td>0.640</td></tr></table> | <table><tr><td>MBP</td><td>2 (20)</td><td>3 (15)</td><td>3 (38)</td><td>0.435</td></tr></table> |
4f4a77cf0f56b3f654be401756ca23982e74a67856b49a8319de345cbd3e7092.png | complex | <table><tr><td rowspan="2">DNA Concentration</td><td rowspan="2">n</td><td rowspan="2">N</td><td rowspan="2">Cleavage(% ± SD)</td><td>Blastocyst development</td><td>EGFP<sup>+</sup> Blastocysts</td><td>Net yield EGFP<sup>+</sup></td></tr><tr><td>(% ± SD)<sup>a</sup></td><td>(% ± SD)<sup>b</sup></td><td>B... | <table><tr><td rowspan="2">DNA Concentration</td><td rowspan="2">n</td></tr><tr></tr><tr><td>0 ng/μL</td><td>3</td></tr><tr><td>5 ng/μL</td><td>3</td></tr><tr><td>20 ng/μL</td><td>3</td></tr><tr><td>50 ng/μL</td><td>3</td></tr></table> | <table><tr><td rowspan="2">N</td><td rowspan="2">Cleavage(% ± SD)</td><td>Blastocyst development</td><td>EGFP+ Blastocysts</td><td>Net yield EGFP+</td></tr><tr><td>(% ± SD)a</td><td>(% ± SD)b</td><td>Blastocysts (% ± SD)c</td></tr><tr><td>57</td><td>49 (86.0 ± 4.9)</td><td>18 (31.6 ± 4.1)d</td><td>0</td><td>0</td></tr>... |
8202fce481deb0cda09aba5fe5ff3e64e59e9ee49cd939cfc7c41bdf6c9628e9.png | simple | <table><tr><td>Characteristics</td><td><i>n</i></td><td>HRM me (%)</td><td>MSP me (%)</td><td>PSQ me (%)</td><td>IDH1 mut (%)</td></tr><tr><td>All patients</td><td>83</td><td>51.8</td><td>37.3</td><td>54.2</td><td>21.7</td></tr><tr><td>Woman</td><td>28</td><td>50.0</td><td>39.3</td><td>53.6</td><td>21.4</td></tr><tr><t... | <table><tr><td>Characteristics</td><td>n</td><td>HRM me (%)</td><td>MSP me (%)</td><td>PSQ me (%)</td><td>IDH1 mut (%)</td></tr><tr><td>All patients</td><td>83</td><td>51.8</td><td>37.3</td><td>54.2</td><td>21.7</td></tr><tr><td>Woman</td><td>28</td><td>50.0</td><td>39.3</td><td>53.6</td><td>21.4</td></tr><tr><td>Man</... | <table><tr><td>Grade IV</td><td>60</td><td>43.3</td><td>30.0</td><td>48.3</td><td>3.3</td></tr></table> |
1c43ddbd66559bf3a1fb625f95bff469daa89031e06bf1b8dab205b1d13095bf.png | simple | <table><tr><td>Age Range</td><td>Number</td><td>Percentage (%)</td></tr><tr><td>1-10</td><td>9</td><td>42.9</td></tr><tr><td>11-20</td><td>5</td><td>23.8</td></tr><tr><td>21-30</td><td>7</td><td>33.3</td></tr><tr><td>Total</td><td>21</td><td>100</td></tr></table> | <table><tr><td>Age Range</td><td>Number</td><td>Percentage (%)</td></tr><tr><td>1-10</td><td>9</td><td>42.9</td></tr></table> | <table><tr><td>11-20</td><td>5</td><td>23.8</td></tr><tr><td>21-30</td><td>7</td><td>33.3</td></tr><tr><td>Total</td><td>21</td><td>100</td></tr></table> |
aa10e72072738a81e38352bb569e44a813d8d7a074b357ce1960dba47aed2caf.png | complex | <table><tr><td>Authors (year of publication)</td><td>Population studied with CD</td><td>Prevalence of thyroid dysfunction</td></tr><tr><td rowspan="3">Collin et al. (1994) [19]</td><td>355</td><td>AITD* (19) 5.4%</td></tr><tr><td></td><td>Autoimmune hypothyroidism (11) 3.1%</td></tr><tr><td></td><td>Graves' disease (7)... | <table><tr><td>Authors (year of publication)</td><td>Population studied with CD</td><td>Prevalence of thyroid dysfunction</td></tr><tr><td rowspan="3">Collin et al. (1994) [19]</td><td>355</td><td>AITD* (19) 5.4%</td></tr><tr><td></td><td>Autoimmune hypothyroidism (11) 3.1%</td></tr><tr><td></td><td>Graves' disease (7)... | <table><tr><td>Authors (year of publication)</td><td>Population studied with CD</td><td>Prevalence of thyroid dysfunction</td></tr><tr><td rowspan="2">Velluzzi et al. (1998) [7]</td><td>47</td><td>Hypothyroid (2) 4.3%</td></tr><tr><td></td><td>Subclinical hypothyroid (3) 6.4%</td></tr><tr><td rowspan="3">Sategna-Guidet... |
bfe8057e72cbc43b57bc13218d4a8815983aa1b512daed5a6e14c107c120fa1d.png | complex | <table><tr><td></td><td colspan="3">Source of help beforehand</td><td colspan="3">Source of help afterwards</td></tr><tr><td></td><td>N = 558*</td><td>N = 137*</td><td>N = 421*</td><td>N = 526*</td><td>N = 133*</td><td>N = 393*</td></tr><tr><td></td><td>N (%)</td><td>Male (%)</td><td>Female (%)</td><td>N (%)</td><td>Ma... | <table><tr><td></td><td colspan="3">Source of help beforehand</td><td colspan="2">Source of help afterwards</td></tr><tr><td></td><td>N = 558*</td><td>N = 137*</td><td>N = 421*</td><td>N = 526*</td><td>N = 133*</td></tr><tr><td></td><td>N (%)</td><td>Male (%)</td><td>Female (%)</td><td>N (%)</td><td>Male (%)</td></tr><... | <table><tr><td>Source of help afterwards</td></tr><tr><td>N = 393*</td></tr><tr><td>Female (%)</td></tr><tr><td>191 (49)</td></tr><tr><td>96 (25)</td></tr><tr><td>11 (3)</td></tr><tr><td>17 (5)</td></tr><tr><td>28 (8)</td></tr><tr><td>29 (8)</td></tr><tr><td>15 (4)</td></tr><tr><td>5 (1)</td></tr><tr><td>14 (4)</td></t... |
828de89f52ec0d03820c906f40b670f2f817236cfe570a55a9493e94ee5dd667.png | complex | <table><tr><td></td><td colspan="3">SCQ total</td><td colspan="3">SRS raw score</td></tr><tr><td><i>Factors</i></td><td><i>B</i></td><td><i>p</i></td><td>95%</td><td><i>B</i></td><td><i>p</i></td><td>95%</td></tr><tr><td>Constant</td><td>12.44</td><td>0.204</td><td>− 7.38/32.25</td><td>− 21.43</td><td>0.615... | <table><tr><td></td><td colspan="3">SCQ total</td><td colspan="3">SRS raw score</td></tr><tr><td>Factors</td><td>B</td><td>p</td><td>95%</td><td>B</td><td>p</td><td>95%</td></tr><tr><td>Constant</td><td>12.44</td><td>0.204</td><td>− 7.38/32.25</td><td>− 21.43</td><td>0.615</td><td>− 109.37/66.50</td></tr><tr><td>Gender... | <table><tr><td></td><td colspan="3">SCQ total</td><td colspan="3">SRS raw score</td></tr><tr><td>Factors</td><td>B</td><td>p</td><td>95%</td><td>B</td><td>p</td><td>95%</td></tr><tr><td>el’s p value</td><td colspan="3">0.0008</td><td colspan="3">.010</td></tr></table> |
44eb94deb13d481771d1622c9126ae2daedd2331e03436e300d82e6bef562353.png | complex | <table><tr><td></td><td colspan="3">GP profession</td><td></td><td></td><td></td><td></td></tr><tr><td># new patients consulted</td><td>US</td><td>UK</td><td>Germany</td><td>France</td><td>Spain</td><td>Italy</td><td>GP total</td></tr><tr><td>0</td><td>20</td><td>5</td><td>2</td><td>-</td><td>1</td><td>1</td><td>29</td... | <table><tr><td></td><td colspan="3">GP profession</td><td></td><td></td><td></td><td></td></tr><tr><td># new patients consulted</td><td>US</td><td>UK</td><td>Germany</td><td>France</td><td>Spain</td><td>Italy</td><td>GP total</td></tr><tr><td>0</td><td>20</td><td>5</td><td>2</td><td>-</td><td>1</td><td>1</td><td>29</td... | <table><tr><td>50-99</td><td>19</td><td>10</td><td>11</td><td>5</td><td>4</td><td>2</td><td>51</td></tr><tr><td>>100</td><td>8</td><td>3</td><td>15</td><td>3</td><td>1</td><td>1</td><td>31</td></tr></table> |
0f894d668a159b8c60b39796bab099e28064094a5dd9807e4be621e99fcdf6fc.png | complex | <table><tr><td>Site</td><td>Characteristic</td><td>Category</td><td>Unadjusted OR (95% CI)</td></tr><tr><td rowspan="9">Nouna</td><td>Malaria treatment in past 14 days</td><td>Yes vs no</td><td>0.323 (0.215, 0.484)</td></tr><tr><td>Other medication in the past 14 days</td><td>Yes vs no</td><td>0.563 (0.403, 0.788)</td>... | <table><tr><td>Site</td><td>Characteristic</td><td>Category</td><td>Unadjusted OR (95% CI)</td></tr><tr><td rowspan="3">Nouna</td><td>Malaria treatment in past 14 days</td><td>Yes vs no</td><td>0.323 (0.215, 0.484)</td></tr><tr><td>Other medication in the past 14 days</td><td>Yes vs no</td><td>0.563 (0.403, 0.788)</td>... | <table><tr><td>Site</td><td>Characteristic</td><td>Category</td><td>Unadjusted OR (95% CI)</td></tr><tr><td rowspan="6">Nouna</td><td>Age</td><td>Continuous</td><td>1.159 (1.086, 1.236)</td></tr><tr><td>Localization</td><td>Rural vs urban area</td><td>2.635 (1.876, 3.701)</td></tr><tr><td>Type of location</td><td>Town ... |
ef681d4e74b2b72f83631f7ff965e66379550e85162f867b1e6feef9c1d5eb75.png | simple | <table><tr><td>Allele</td><td>Slope</td><td>Efficiency (%)</td><td><i>R</i><sup>2</sup></td><td><i>y</i>-intercepts</td></tr><tr><td>Wild-type-sensitive</td><td>3.39</td><td>97.2</td><td>0.998</td><td>37.705</td></tr><tr><td>Mutant-resistant</td><td>2.59</td><td>142.7</td><td>0.991</td><td>36.531</td></tr></table> | <table><tr><td>Allele</td><td>Slope</td><td>Efficiency (%)</td><td>R2</td><td>y-intercepts</td></tr><tr><td>Wild-type-</td><td>3.3</td><td>97.</td><td>0.998</td><td>37</td></tr></table> | <table><tr><td>sensitive</td><td>9</td><td>2</td><td></td><td>.705</td></tr><tr><td>Mutant-resistant</td><td>2.59</td><td>142.7</td><td>0.991</td><td>36.531</td></tr></table> |
8c0dd92b8a307ae3f5c87438b23d5dca8e8b9de6421a9a12db30e8828804b562.png | simple | <table><tr><td></td><td>Women</td><td>Men</td><td>All</td></tr><tr><td>N</td><td>32</td><td>27</td><td>59</td></tr><tr><td>Age (years)</td><td>39.3 ± 10.5</td><td>39.3 ± 11.0</td><td>39.3 ± 10.6</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>23.2 ± 3.1</td><td>25.8 ± 3.6**</td><td>... | <table><tr><td></td><td>Women</td><td>Men</td></tr><tr><td>N</td><td>32</td><td>27</td></tr><tr><td>Age (years)</td><td>39.3 ± 10.5</td><td>39.3 ± 11.0</td></tr><tr><td>Body mass index (kg/m2)</td><td>23.2 ± 3.1</td><td>25.8 ± 3.6**</td></tr><tr><td>Total cholesterol (mmol/l)</td><td>5.23 ± 0.87</td><td>5.76 ± 1.02*</t... | <table><tr><td>All</td></tr><tr><td>59</td></tr><tr><td>39.3 ± 10.6</td></tr><tr><td>24.4 ± 3.6</td></tr><tr><td>5.47 ± 0.97</td></tr><tr><td>1.35 ± 0.71</td></tr><tr><td>1.65 ± 0.38</td></tr><tr><td>3.21 ± 0.96</td></tr><tr><td>1.59 ± 0.21</td></tr><tr><td>0.90 ± 0.23</td></tr><tr><td>220 ± 219</td></tr><tr><td>4.5 ± ... |
9d453dbbb0ecff3e71c45bce96b7e63b42546b647dd2faef0f00f467da40820d.png | simple | <table><tr><td></td><td>cTAKES [4]</td><td>NOBLE Coder [20]</td><td>MetaMap [31, 32]</td><td>NCBO annotator [14]</td></tr><tr><td>Modularity/configuration options</td><td>Modular text processing pipeline</td><td>Vocabulary (terminology);Term matching options and strategies</td><td>Text processing pipeline;Vocabulary (t... | <table><tr><td></td><td>cTAKES [4]</td><td>NOBLE Coder [20]</td><td>MetaMap [31, 32]</td><td>NCBO annotator [14]</td></tr><tr><td>Modularity/configuration options</td><td>Modular text processing pipeline</td><td>Vocabulary (terminology);Term matching options and strategies</td><td>Text processing pipeline;Vocabulary (t... | <table><tr><td>(terminology)</td><td>LS, namely SNOMED CT and RxNORM</td><td>s, based on subsets of UMLS(e.g. SNOMED CT, MeSH, RxNORM)</td><td>athesaurus</td><td>es (over 330 ontologies)</td></tr><tr><td>Speed*</td><td>Suitable for real-time processing</td><td>Suitable for real-time processing</td><td>Better for off-li... |
0995497eb43985d4654fa71f7f615eade325f331e6c530eda96ed30f6afb15bd.png | simple | <table><tr><td>Eukaryotic organisms</td><td>%</td><td>Prokaryotic organisms</td><td>%</td></tr><tr><td><i>Chloromonas pseudoplatyrhyncha</i></td><td>26.93</td><td><i>Rhodoferax</i> sp.</td><td>21.94</td></tr><tr><td><i>Stephanodiscus</i> sp.</td><td>18.17</td><td>Unsequenced organisms</td><td>17.84</td></tr><tr><td>Uns... | <table><tr><td>Eukaryotic organisms</td><td>%</td><td>Prokaryotic organisms</td><td>%</td></tr></table> | <table><tr><td>Chloromonas pseudoplatyrhyncha</td><td>26.93</td><td>Rhodoferax sp.</td><td>21.94</td></tr><tr><td>Stephanodiscus sp.</td><td>18.17</td><td>Unsequenced organisms</td><td>17.84</td></tr><tr><td>Unsequenced organisms</td><td>17.87</td><td>Flavobacterium sp.</td><td>9.43</td></tr><tr><td>Chromulinaceae sp.<... |
fb0c6e0caf71001e43b2b06573f16cb352f0905d3fef89f8d8381aa1c0f062a1.png | simple | <table><tr><td> </td><td>Women using long-acting reversible contraception<sup>+</sup>(<i>n</i> = 866)Percentage</td><td>Women using highly effective short-term reversible contraception<sup>∧</sup> (<i>n</i> = 12,098)Percentage</td><td>UnivariableOR (95% CI)</td><td>Multivariable OR (95% CI)</td></tr><tr><td>Age<s... | <table><tr><td></td><td>Women using long-acting reversible contraception+(n = 866)Percentage</td><td>Women using highly effective short-term reversible contraception∧ (n = 12,098)Percentage</td><td>UnivariableOR (95% CI)</td><td>Multivariable OR (95% CI)</td></tr><tr><td>Age∗</td><td></td><td></td><td></td><td></td></t... | <table><tr><td></td><td>Women using long-acting reversible contraception+(n = 866)Percentage</td><td>Women using highly effective short-term reversible contraception∧ (n = 12,098)Percentage</td><td>UnivariableOR (95% CI)</td><td>Multivariable OR (95% CI)</td></tr><tr><td>2006</td><td>1.5%</td><td>8.3%</td><td>0.70 (0.3... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.